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1. Introduction 
In this report, results are summarised from the ninth proficiency test trial conducted by the 
National Food Institute (DTU Food) as the EU Reference Laboratory for Antimicrobial 
Resistance (EURL-AR). This proficiency test focuses on Salmonella and Campylobacter and is 
the fifth External Quality Assurance System (EQAS) conducted for these microorganisms (the 
first was EQAS 2006).  
The objective of the EQAS is to monitor the quality of the antimicrobial susceptibility data 
produced by the NRL-AR and to identify areas or laboratories, for which guidance or 
assistance would be required as means of producing reliable susceptibility data. The goal until 
the 2008 iteration was to have all laboratories performing antimicrobial susceptibility testing 
(AST) with less than 7% incorrect interpretations. This was reconsidered at the EURL-AR 
workshop 2009, and as of the 2009 iterations, the goal is to have each laboratory performing 
AST with less than 5% incorrect interpretations (interpretations deviating from the expected 
results). 
The data in this report are presented with laboratory codes. A laboratory code is known to the 
individual laboratory, whereas the entire list of laboratories and their codes is confidential and 
known only to the EURL-AR and the EU Commission. All conclusions are public.  
The technical advisory group for the EURL-AR EQAS scheme consists of competent 
representatives from all National Reference Laboratories (NRLs), who meet once a year at the 
EURL-AR workshop.  
The AST data reported to EFSA by the Member States (MS) is based on the interpretation of 
the AST results. This is the basis for this EQAS evaluating the interpretation; as is also stated in 
the protocol, the “main objective of this EQAS is to assess and improve the comparability of 
surveillance and antimicrobial susceptibility data reported to EFSA by the different NRLs”. In 
addition, the participants of an EQAS should evaluate their own results and introduce 
corrective actions if necessary. The categorization of an uploaded interpretation as incorrect in 
the EURL-AR EQAS should induce the participant to perform a self-evaluation. This self-
evaluation could very well include a comment on the fact that the MIC value for strain 
frequently varies by one dilution step either way, which in some cases affect the interpretation 
of the result. Therefore, the self-evaluation may lead to arguments which can defend the 
obtained results internally, yet, incorrect interpretations based on a one step dilution difference 
is still regarded as a deviation for the overall EQAS reporting, evaluation and in the database. 
The EURL-AR is accredited by DANAK (accreditation no. 516) as provider of proficiency test 
for zoonotic pathogens and indicator organisms in bacterial isolates (serotyping, identification, 
and antimicrobial susceptibility testing). 
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2. Materials and methods 
2.1 Participants 
A pre-notification (App. 1) of the EURL-AR EQAS on AST of Salmonella and Campylobacter 
was distributed on the 20th
Appendix 2 shows that 33 of the 37 participating NRLs were appointed by the individual 
Member States. Two NRLs were enrolled on equal terms as the designated NRLs, based on 
their participation in an EU funded concerned action (FAIR5-QLK2-2002-01146), the ARBAO 
II project (Antibiotic Resistance in Bacteria of Animal Origin). The laboratories in Iceland, 
Norway, Serbia and Switzerland were charged a fee for their participation in the EQAS, 
whereas the NRLs from EU Member States participated free of charge. 
 August 2010 by e-mail to the 40 NRLs in the EURL-AR-network 
(including Iceland, Norway, Serbia and Switzerland). In addition, to the AST of Salmonella 
and Campylobacter, an optional genotypic characterization by PCR/sequencing of 
antimicrobial resistance genes of a selected Enterococcus faecium and Shigella spp. isolate was 
offered. The pre-notification was sent to NRLs in all EU countries except Luxemburg, where 
no NRL has been designated. All 37 laboratories responded. One laboratory declined to 
participate as they had neither Salmonella nor Campylobacter as their field of responsibility. In 
addition, Iceland and Serbia did not participate in this iteration. 
Figure 1: Participating countries that performed antimicrobial susceptibility testing of Salmonella or 
both Salmonella and Campylobacter.  
Figure 1 shows that out of 28 participating countries, two uploaded only the Salmonella results 
(Bulgaria and Greece), whereas 26 tested both Salmonella and Campylobacter. The results 
from the designated NRLs are presented and evaluated in this report; i.e. results from 26 
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countries consisting of 31 sets of Salmonella results and 27 sets of Campylobacter results. Four 
laboratories participated in the optional genotypic characterisation of the E. faecium and/or the 
Shigella spp. isolate (not illustrated in Figure 1). 
2.2 Strains 
Eight Salmonella strains and eight Campylobacter strains were selected for this trial among 
isolates from the strain collection at DTU Food. Individual sets of the Salmonella strains were 
provided as agar stab cultures and the Campylobacter strains as charcoal swabs. 
The shipment of strains also included the lyophilised international reference strains for 
antimicrobial susceptibility testing; Escherichia coli CCM 3954 (ATCC 25922) and 
Campylobacter jejuni CCM 6214 (ATCC 33560) purchased at Czech Collection of Micro-
organisms (CCM), the Czech Republic. This was relevant only for the NRLs which had not 
been provided with these reference strains in previous EQAS’s conducted by DTU Food. 
Prior to distribution of the strains, antimicrobial susceptibility testing (AST) on the Salmonella 
and Campylobacter strains was performed at DTU Food and verified by the US Food and Drug 
Administration (FDA). The obtained MIC values served as reference for the test strains (App. 
3a and 3b). However, results from the following antimicrobials were not verified by FDA: 
cefotaxime, cefotaxime/clavulanic acid, ceftazidime, ceftazidime/clavulanic acid, imipenem, 
imipenem/EDTA, and trimethoprim for Salmonella. Furthermore, chloramphenicol and 
streptomycin for Campylobacter. 
The test strains offered for optional genotypic characterisation were an Enterococcus faecium 
(EURL GEN 2.1) exhibiting resistance to ampicillin, erythromycin, kanamycin, moxifloxacin, 
penicillin, streptomycin, tetracycline, and vancomycin, and a Shigella spp. (EURL GEN 2.2) 
exhibiting resistance to ampicillin, cephalothin, cefpodoxime, ceftiofur, chloramphenicol, 
ciprofloxacin, nalidixic acid, spectinomycin, streptomycin, sulfamethoxazole, tetracycline, and 
trimethoprim (selection of antimicrobials was different from those used for the AST in this 
EQAS). 
2.3 Antimicrobials 
The antimicrobials used in the EQAS are listed in the protocol (App. 4b) and were included 
mainly according to the recommendations of the European Food Safety Authority (EFSA) 
monitoring programme (Report of the Task Force of Zoonoses Data Collection including a 
proposal for a harmonized monitoring scheme of antimicrobial resistance in Salmonella in fowl 
(Gallus gallus), turkeys, and pigs and Campylobacter jejuni and C. coli in broilers, the EFSA 
Journal (2007), 96,1-46). A few additional antimicrobials have been added as indicated in the 
protocol due to included element on detection of ESBL production. 
The selection of antimicrobials used in the trial for Salmonella was: ampicillin, cefotaxime, 
cefotaxime/clavulanic acid, ceftazidime, ceftazidime/clavulanic acid, ceftiofur, 
chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, streptomycin, sulfonamides 
(sulfamethoxazole), tetracycline and trimethoprim. Additionally, cefoxitin was used for 
detection of AmpC, and imipenem, imipenem/EDTA for detection of metallo-beta-lactamases. 
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Minimum Inhibitory Concentration (MIC) determination of the Salmonella test strains was 
performed using the Sensititre system from Trek Diagnostic Systems Ltd, UK. For ESBL 
confirmatory test, the analysis included microbroth dilution MIC determination (including 
imipenem), and for the antimicrobials cefotaxime/clavulanic acid, cefoxitin, 
ceftazidime/clavulanic acid additional tests using E-test from AB-Biodisk, Sweden. The 
method guidelines used were according to the Clinical and Laboratory Standards Institute 
(CLSI) document M7-A7 (2006),
For Campylobacter the following antimicrobials were included: chloramphenicol, 
ciprofloxacin, erythromycin, gentamicin, nalidixic acid, streptomycin, and tetracycline. MIC 
determination was performed using the Sensititre systems from Trek Diagnostic Systems Ltd, 
UK, according to guidelines from the CLSI document M45-A (2006) “Methods for 
Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious 
Bacteria” (Approved Guideline) and M31-A3 (2008) “Performance Standards for 
Antimicrobial Disk and Dilution Susceptibility Tests for Bacterial Isolated From Animals” 
(Approved Standard – Third Edition). 
 “Methods for Dilution Antimicrobial Susceptibility Tests for 
Bacteria That Grow Aerobically” (Approved Standard - Seventh Edition), document M100-S20 
(2010) “Performance Standards for Antimicrobial Susceptibility Testing” (Twentieth 
Informational Supplement) and document M31-A3 (2008) “Performance Standards for 
Antimicrobial Disk and Dilution Susceptibility Tests for Bacterial Isolated From Animals” 
(Approved Standard – Third Edition). 
2.4 Distribution 
On October 25th
International Air Transport Association
, 2010, the cultures and a welcome letter (App. 4a) were dispatched in double 
pack containers (class UN 6.2) to the participating laboratories as UN3373, biological 
substance category B, according to the  (IATA) 
regulations.  
2.5 Procedure 
Through the EURL-AR website, http://www.eurl-ar.eu/, the laboratories were provided with 
protocols and information regarding the handling of the test strains and reference strains (App. 
4b, c, d, e). The participants were instructed to subculture the strains according to the 
description in the protocol prior to performing the AST. Furthermore, they were requested to 
save and maintain the ATCC reference strain(s) for future proficiency tests. 
The aim is that only MIC methods are used when performing AST for monitoring conducted by 
the Commission, and thereby also when performing the EURL-AR EQAS’s. Consequently, it 
was decided in May 2007 by the participants at the EURL-AR workshop that the NRLs should 
work towards harmonising to MIC methods for these AST analyses. Additionally, it was agreed 
that all NRLs should work towards covering the antimicrobial panel and epidemiological cut-
off values recommended by the EURL-AR. For this EQAS, the participants were instructed to 
use as many as possible of the antimicrobials listed, using the method carried out when 
performing monitoring for EFSA. 
The cut-off values recommended by EFSA should be used (listed in the protocol). All cut-off 
values used in the interpretation of the Campylobacter MIC results have been developed by 
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EUCAST (www.eucast.org). This is also the case for Salmonella with the exception of 
sulphonamides, where the value from CLSI was used according to the description in the 
protocol (App. 4b).  
Participants using disk diffusion (DD) and E-test were recommended to interpret the results 
according to their individual routine, categorising the test strains into the terms resistant and 
susceptible. A categorisation as ‘intermediate’ was not accepted. In these cases, the breakpoints 
used were submitted to the web based database, from which the relevant breakpoints (disk 
diffusion for Salmonella) are listed in Appendix 5.  
It should be noted that for AST of Campylobacter only MIC methods are recommendable, i.e. 
broth or agar dilution methods. The EURL-AR does not recommend the use of either disk 
diffusion or E-test for AST of Campylobacter. In addition, when reporting monitoring data to 
EFSA these have to be submitted as MIC-results. It was agreed at the EURL-AR workshop 
2009 that only MIC results for Campylobacter ASTs are accepted.  
The laboratories were instructed to upload the obtained MIC values (mg/L) or inhibition zone 
diameters (mm) and the susceptibility categories (resistant or susceptible) to an electronic 
record sheet in the EURL-AR web based database through a secured individual login. 
Alternatively, the record sheets from the protocol could be sent by fax to DTU Food. The 
website was open for data entry in the period from the 4th of November 2010 to the 17th
Detection of ESBL-producing strains should be performed and interpreted according to 
recommendations by EUCAST described in the protocol. Concerning cefotaxime, ceftazidime 
and/or ceftiofur used when detecting ESBL-producing strains in this EQAS, MIC values and 
interpretations for these antimicrobials should be reported as found.  
 of 
January 2011. 
Results from the reference strains should also be entered into the database. The results would 
consist of MIC values for the reference strains E. coli (ATCC 25922) and C. jejuni (ATCC 
33560) or, for E. coli (ATCC 25922), the inhibition zone diameters in millimetres. The results 
should be in agreement with the quality control ranges according to the relevant guidelines; the 
CLSI documents M31-A3 (2008) / M100-S20 (2010) / M45-A (2006); The Sensititre System 
(Trek Diagnostic Systems Ltd, UK); or E-tests (AB-Biodisk, Sweden) (App. 7). 
For the optional PCR-testing of the selected Gram-positive and Gram-negative isolate, 
participating laboratories were requested to report the genes harboured in the test strain. The 
genes listed in the table in the protocol (App. 4b) were included in the test. Identification of 
additional genes not listed in the protocol was not evaluated. The results were evaluated based 
on the actual genes identified. The variants of TEM-, CTX-, SHV-, CMY-, OXA-genes as well 
as the gyrA-mutations and parC-mutations were additionally evaluated. For gyrA and parC, the 
point of mutation at a specific codon was evaluated in the same way as the genes.  
The participating laboratories were encouraged to use their own laboratory’s method(s) for the 
PCR-testing. The expected results for the Gram-positive strain were obtained by the EURL-
AR’s routine PCR-methods, whereas the expected results for the Gram-negative strain were 
obtained at the EURL-AR by using miniaturized microarrays (Identibac Amr-ve array tubes; 
New Haw, Addlestone, Surrey, United Kingdom) containing probes for most relevant Gram-
negative antimicrobial resistance gene groups such as quinolone, sulfonamide, tetracycline, 
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aminoglycoside, carbenicillinase, chloramphenicol exporter/acetyltransferase, florfenicol, 
trimethoprim, plasmidic AmpC, beta-lactam antimicrobials as well as class 1/2 integrase. 
Analysis was performed as recommended by the manufacturer. PCR was conducted for 
confirmation of weak array results. The results for both strains were verified by the US FDA. 
After submitting the data, the laboratories were instructed to retrieve the instantly generated, 
individual evaluation report from the secured web site. The evaluation reports assessed the 
submitted results, describing all deviations from the expected. Deviations in the interpretation 
as resistant or susceptible were categorised as ‘incorrect’, as was also deviations in 
confirmation of an isolate as ESBL-producer or AmpC.  
The EURL-AR is aware that there are two different types of interpretative criteria of results, 
clinical breakpoints and epidemiological cut-off values. The terms ‘susceptible’, ‘intermediate’ 
and ‘resistant’ should be reserved for classifications made in relation to the therapeutic 
application of antimicrobial agents. When reporting data using epidemiological cut-off values, 
bacteria should be reported as ‘wild-type’ or ‘non-wild-type’ (Schwarz et al., 2010). Due to the 
different methods of AST used by the participants and also to simplify the interpretation of 
results, throughout this report, we will still maintain the terms susceptible and resistant, even in 
the cases where we are referring to wild-type and non-wild-type strains. 
The database included questions for evaluation of the EQAS as well as questions regarding the 
individual laboratories’ work in the area of AST. Few laboratories used these features for 
sending comments to the EURL, those who did have received direct reply when relevant. Test 
ranges for concentrations used when performing MIC for AST were collected in Appendix 8. 
 
3. Results 
The participants were asked to report results, including MIC values or inhibition zone 
diameters obtained by DD together with the categorisation as resistant or susceptible. Only the 
categorisation was evaluated, whereas the MIC values and disk diffusion inhibition zones were 
used as supplementary information. 
At the EURL-AR workshop 2008, the network agreed that if less than 75% of the results were 
correct, based on strain/antimicrobial combination, these results should be further analysed and 
possibly omitted from evaluation. In the present EQAS this occurred in two cases: for the 
combination of the test strains S-5.2/streptomycin and S-5.3/streptomycin with a level of 
agreement with the expected results at 47% and 27%, respectively (Appendix 9a and 9b present 
the total percentage of correct/incorrect results for each strain/antimicrobial-combinations).  
In both cases, the expected MIC (32 mg/L, resistant) and the cut-off value (>16 mg/L) were 
within one fold dilution difference. The expected values were determined by two different 
institutions; DTU Food and FDA and were consistent with MIC results of 32mg/L or ≤32mg/L. 
For both test strains, S-5.2 and S-5.3, the presence of aadA was confirmed by PCR by the 
EURL-AR, whereas the genes strA and strB were not detected in either of the two test strains.  
Figure 2 illustrates the distribution of the different MIC values together with the interpretation 
of these values obtained by participants performing MIC for the combination of strain S-
5.2/streptomycin and S-5.3/streptomycin. The figure shows a distribution of MIC’s with the 
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expected value at 32mg/L and the majority of participants obtaining AST results one MIC-
dilution below the expected result. Results from four participants performing disk diffusion 
have been excluded from these particular analyses. 
 
Figure 2: Distribution of the different MIC values obtained by participants performing MIC for the 
combination S-5.2/streptomycin and S-5.3/streptomycin. 
This data was presented and discussed at the EURL-AR workshop, and it was concluded to 
exclude these two strain/antimicrobial combinations of the evaluation. This conclusion was 
based on the fact that the precision of the method relies on various factors, including the media 
content, the type of microbroth panels as well as a number of others, and the fact that an MIC 
result obtained by the microbroth method or agar dilution can vary +/- one dilution step from 
the obtained MIC. 
3.1 Methods used by EQAS-participants 
In the Salmonella trial, 27 laboratories used MIC determination, and four laboratories used disk 
diffusion. For the Campylobacter trial, all 27 laboratories reported the use of MIC 
determination (microbroth or agar dilution).  
            
Figure 3: A comparison between the EURL-AR EQAS’s since 2006, showing the total percentage of 
deviations for antimicrobial susceptibility testing performed by participating laboratories  
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3.2 Deviations by strain and antimicrobial 
The list of deviations is shown in Appendix 10a and 10b. Figure 3 shows the total percentage of 
deviations from the expected results of AST performed by participating laboratories. For the 
Salmonella strains, 97.8% of the AST’s were interpreted correctly. For the Campylobacter 
strains, 98.0% of AST’s were correctly tested. The internal control strains have mainly 
followed the trend in deviation level of the different EQAS trials (Figure 3). However, for the 
Campylobacter trial, the internal control strain caused no deviations. The deviation level in 
2010 is acceptable for both the Salmonella and the Campylobacter trials.  
 
Figure 4: The total percentage of deviations for AST’s performed using MIC-methods as opposed to 
disk diffusion.  
Figure 4 shows the total percentage of deviations from the expected results of AST performed 
by MIC-methods as opposed to disk diffusion. This is relevant for the Salmonella trial for 
which the deviation percentage is significantly higher (p<0.01) when AST is performed by disk 
diffusion compared to a MIC-method.   
EQAS 2010 – Salmonella EQAS 2010 – Campylobacter 
Test strain AST in total % correct Test strain AST in total % correct 
S-5.1 341 98.8   C-5.1 (C. jejuni) 182 100.0 
S-5.2 311 97.4   C-5.2 (C. coli) 182 97.3 
S-5.3 310 97.4   C-5.3 (C. coli) 181 97.2 
S-5.4 341 99.4   C-5.5 (C. coli) 181 95.6 
S-5.5 341 96.5   C-5.5 (C. coli) 182 97.3 
S-5.6 341 97.7   C-5.6 (C. coli) 182 98.4 
S-5.7 340 96.2   C-5.7 (C. jejuni) 174 98.3 
S-5.8 342 99.1   C-5.8 (C. jejuni) 174 100.0 
Table 1: The number of AST performed and the percentage of correct results for each strain of 
Salmonella and Campylobacter.  
The number of AST’s performed and the percentage of correct results for the individual 
Salmonella and Campylobacter strains in the EQAS, are listed in Table 1. Variations of 
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obtained correct results ranged from 96.2-99.4% for Salmonella and from 95.6-100% for 
Campylobacter. 
For Salmonella, the test strain S-5.7 was also included in former EQAS’s as internal reference 
strain. Figure 3 indicates the variation in deviation level over the years. This strain is resistant 
to ampicillin, cefotaxime, ceftiofur, ciprofloxacin, nalidixic acid, and tetracycline. In former 
EQASs, this strain was also regarded as resistant towards ceftazidime, but due to a change in 
the EUCAST expert rules, MIC’s for all cephalosporins should be evaluated and reported as 
found. 
Table 2 illustrates the percentage of correct AST per antimicrobial by bacterial species. When 
testing Salmonella, it appeared that the antimicrobial with the lowest percentage of correct AST 
was ciprofloxacin (90.8%) which could be attributed to some of to the six test strains exhibiting 
reduced susceptibility towards this antimicrobial.  
EQAS 2010 % correct 
Antimicrobial Salmonella Campylobacter 
Ampicillin, AMP 99.6 - 
Cefotaxime, CTX 99.6 - 
Ceftazidime, CAZ 97.9 - 
Ceftiofur, XNL 100.0 - 
Chloramphenicol, CHL 99.2 100.0 
Ciprofloxacin, CIP 91.1 99.1 
Erythromycin, ERY - 99.1 
Gentamicin, GEN 98.8 100.0 
Nalidixic acid, NAL 96.0 97.7 
Streptomycin, STR 96.3 95.6 
Sulphonamides, SMX 98.4 - 
Tetracycline, TET 98.4 94.8 
Trimethoprim, TMP 100.0 - 
Table 2: Percentage of correct antimicrobial susceptibility tests per antimicrobial by microorganism. 
In grey, antimicrobials recommended in the EFSA zoonosis monitoring manual.  
For Campylobacter, none of the antimicrobials had a notably outlying deviation level.  
ESBL-producing Salmonella test strains 
It was decided on the EURL-AR workshop 2008 that the testing of ESBL production in 
Salmonella should be mandatory. The laboratories were asked to detect the ESBL-producing 
Salmonella strains and to perform confirmatory testing on all relevant strains resistant to 
cefotaxime (CTX), ceftazidime (CAZ) or ceftiofur (XNL) according to the protocol (App. 4b).  
The two test strains S-5.7 and S-5.8 were ESBL-producers, and this was confirmed by the 
majority of the 31 laboratories participating in the Salmonella EQAS. As the ESBL detection 
part is mandatory in this EQAS, all results are evaluated below. 
Both ESBL-producing strains were so-called ‘true ESBLs, harbouring blaCTX M-15-like (S-5.7) 
and blaCTX M-15 (S-5.8) (Table 3).  
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There is a difference in the number of cephalosporins used by the laboratories in their routine 
test for ESBL production; five compounds are included in this proficiency test: cefotaxime, 
ceftazidime, ceftiofur, cefotaxime/clavulanic acid and ceftazidime/clavulanic acid. The first 
three are used for initial screening whereas the last two are used for confirmatory test (the 
combination disk method).  
 
Strain S-5.7 
(CTX M-15 like) 
Strain S-5.8 
(CTX M-15) 
Proportion of 
laboratories succesfully 
using different 
cephalosporins for 
screening 
(correct confirmation of 
ESBL production) 
CTX, CAZ, XNL 6/6 (100%) 6/6 (100%) 
CTX, CAZ 18/18 (100%) 17/18 (94%) 
CTX, XNL 1/1 (100%) 1/1 (100%) 
CTX 4/6 (67%) 4/6 (67%) 
Confirmed ESBL-producer 29/31 (93%) 28/31 (90%) 
FOX 31/31 (100%) S 31/31 (100%) 
AmpC not confirmed 31/31 (100%) 31/31 (100%) 
Table 3: Proportion of laboratories that obtained the expected result. Number and percentages of 
laboratories which correctly detected and confirmed the ESBL-producing Salmonella strains.  
In five occasions, the ESBL-producing strain was not detected. Four of these deviations were 
due to two laboratories which did not perform the confirmatory testing (laboratory #38 and 
#39) which was also the case in EURL-EQAS 2009. The remaining case appears to be a lapse  
 
Figure 5: Individual participants’ deviations in percent of their total number of Salmonella AST’s. An 
asterisk indicates that the laboratory performed AST using disk diffusion 
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of registration in the database, as the uploaded screening and confirmatory results were all in 
agreement with the expected.  
Thirteen laboratories uploaded an MIC-ratio as a result, and 14 uploaded the increase of 
inhibition zone diameter, additionally, two laboratories uploaded both an MIC and an inhibition 
zone diameter result. All results uploaded on confirmatory tests were in accordance with the 
expected, and led to the correct confirmation of ESBL production in all cases with the 
exception mentioned above.  
According to the expected results, none of the laboratories reported resistance to 
cephalosporins for any of the non-ESBL-producing strains.  
3.3 Deviations by laboratory 
Figure 5 and 7 illustrate the percentage of deviations for each participating laboratory. The 
laboratories are ranked according to their performance determined by the percentage of 
deviating results in tests with antimicrobials recommended by EFSA. These results will be the 
focus of the evaluation in the following sections. Obtained results including all antimicrobials 
mentioned in the protocol are additionally indicated. In Figure 6 and 8, the total amount of 
deviations in percentages is illustrated by number of laboratories.  
3.3.1 Salmonella trial  
Twenty-five of the laboratories obtained a result within the acceptance limit at 5% deviations 
for the Salmonella strains. The maximum percentage of deviations was 12.8%. 
  
Figure 6: The number of laboratories listed in intervals of percent of total deviations. The 
green line marks the 5% acceptance limit set by the EURL-AR 
Figure 6 illustrates the performance of six (19%) laboratories which resulted in a deviation 
level above the level of performance expected by the EURL-AR (#13, #15, #18, #39, #40, and 
#41), however, none of the laboratories are regarded as outliers. As illustrated in Figure 5, 
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deviation levels including all antimicrobials mentioned in the protocol do not vary much from 
the deviation levels regarding EFSA-antimicrobials, only.  
3.3.2 Campylobacter trial 
In the Campylobacter trial most laboratories performed very well. Applying the 5% acceptance 
threshold, 22 of 27 participating laboratories performed acceptably, with 17 laboratories having 
no deviations (Figure 7 and 8). Five laboratories present a deviation level above the 5% 
acceptance level (#19, #21, #22, #30, and #44). No laboratories are regarded as outliers.  
 
Figure 7: Individual participants’ deviations in percent of their total number of Campylobacter AST’s.  
  
Figure 8: The number of laboratories listed in intervals of percent of total deviations.  
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Deviation levels including results obtained for all antimicrobials mentioned in the protocol vary 
to a relatively high extent from the deviation levels including results obtained for 
antimicrobials recommended by EFSA, only. The higher deviation levels generally showing for 
the latter group of antimicrobials. 
3.4 Deviations by reference strains  
In this section, deviations are defined as results of antimicrobial susceptibility tests on the 
reference strain that are outside the quality control (QC) acceptance intervals (App. 7). Values 
from the participants’ testing of the QC strains are listed in Appendix 6a and 6b, and in Tables  
EQAS 2010 Disk diffusion E. coli ATCC 25922 
  Proportion of 
labs outside 
QC range  
Obtained values in mm inhibition zones (min/max) 
Antimicrobial Below lower QC limit Above upper QC limit 
Ampicillin, AMP 1/4 (25%) - 2 
Cefotaxime, CTX 1/4 (25%) - 1 
Cefoxitin, FOX 0/4 (0%) - - 
Ceftazidime, CAZ 0/3 (0%) - - 
Ceftiofur, XNL  1/3 (33%) 2 - 
Chloramphenicol, CHL 0/4 (0%) - - 
Ciprofloxacin, CIP 0/4 (0%) - - 
Gentamicin, GEN 0/4 (0%) - - 
Imipenem, IMI 1/3 (33%) - 3 
Nalidixic acid, NAL 0/4 (0%) - - 
Streptomycin, STR 0/4 (0%) - - 
Sulphonamides, SMX 0/3 (0%) - - 
Tetracycline, TET 0/4 (0%) - - 
Trimethoprim, TMP 0/4 (0%) - - 
Table 4: Obtained values for AST of E. coli ATCC 25922 by disk diffusion.  
EQAS 2010 MIC determination E. coli ATCC 25922 
 Proportion of labs 
outside QC range  
Obtained values in MIC steps (min/max) 
Antimicrobial Below lower QC limit Above upper QC limit 
Ampicillin, AMP 0/27 (0%) - - 
Cefotaxime, CTX 0/26 (0%) - - 
Cefoxitin, FOX 0/4 (0%) - - 
Ceftazidime, CAZ 0/19 (0%) - - 
Ceftiofur, XNL  0/2 (0%) - - 
Chloramphenicol, CHL 0/27 (0%) - - 
Ciprofloxacin, CIP 2/27 (8%) - 1 step 
Gentamicin, GEN 0/27 (0%) - - 
Nalidixic acid, NAL 0/26 (0%) - - 
Streptomycin, STR 1/25 (4%) 1 step - 
Sulphonamides, SMX 0/17 (0%) - - 
Tetracycline, TET 0/27 (0%) - - 
Trimethoprim, TMP 0/25 (0%) - - 
Table 5: Obtained values for AST of E. coli ATCC 25922 by MIC determination 
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4, 5 and 6 which summarize results from the laboratories’ quality control. For the Salmonella 
trial, all laboratories performed QC testing of the reference strain. For the Campylobacter trial, 
25 of the 27 participating laboratories uploaded data from QC-testing on the reference strain. 
Table 4 presents the proportion of laboratories that obtained values out of range for the E. coli 
reference strain (ATCC 25922), when performing disk diffusion. For four out of 14 
antimicrobials, a value outside the QC-range was obtained. Three of these values were 
uploaded by one laboratory (#15).  
The use of MIC determination for AST of the reference strain E. coli ATCC 25922 resulted in 
submission of data from twenty-six laboratories, three of which produced one value each 
outside the QC-limit as illustrated in Table 5.  
EQAS 2010 MIC determination C. jejuni ATCC 33560 
 Proportion of labs 
outside QC range  
Obtained values in MIC steps (min/max) 
Antimicrobial Below lower QC limit Above upper QC limit 
Chloramphenicol, CHL 0/16 (0%) - - 
Ciprofloxacin, CIP 1/25 (4%) - 3 steps 
Erythromycin, ERY 2/25 (8%) 1 step 1 step 
Gentamicin, GEN 4/18 (22%) 1 step - 
Nalidixic acid, NAL 0/22 (0%) - - 
Tetracycline, TET 2/22 (9%) - 1 step 
Table 6: Obtained values for AST of C. jejuni ATCC 33560 using MIC determination 
Twenty-five laboratories performed MIC determination for the C. jejuni reference strain ATCC 
33560. Table 6 presents the proportion of the laboratories with results for the QC strain below 
or above the QC interval. Deviations were seen for four antimicrobials with ciprofloxacin 
exhibiting the largest deviation (3 steps above the upper QC-limit).  
3.5 Genotypic characterisation 
For the optional PCR-testing of selected isolates, one and four laboratories performed the 
genotypic characterization on the Gram positive test strain GEN 2.1 and the Gram negative test 
strain GEN 2.2, respectively. In Appendix 11, there is information on detected genes, on genes 
which were tested but not detected, on primers used, and references for the method used. Table 
7 shows that for all the uploaded results there is good correlation with the expected genes.  
For GEN 2.1, the participating laboratory reported the presence of the tet(K) gene in addition to 
the genes expected by the EURL. The primers used at the EURL-AR for amplifying the tet(K)-
gene are known to also amplify the tet(L)-gene and thereby render a false positive result for 
tet(K) when tet(L) is present and tet(K) is not. Therefore, both PCR products were sequenced to 
detect a possible false positive result; both the presumptive tet(K) and the tet(L) were verified 
as amplicons of tet(L).  
For the GEN 2.2, two laboratories recorded the expected result, CTX-M-14, whereas one 
recorded the CTX-M-9-group (which also includes the CTX-M-14 variant). In addition, due to 
the fact that the EQAS-organisers during the preparations were not able to attribute the detected 
OXA-gene to either OXA-1 or OXA-30, it was decided to add both of these to the list of 
expected genes for the Gram-negative isolate.  
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Two of the four participants recorded that the majority or all of the utilized PCR-methods were 
published, whereas one made use of in-house PCR-methods and one did not upload information 
as to the methods used. One laboratory informed of the use of a microarray (Clondiag, VLA, 
UK; Identibac). 
  Lab I Lab III Lab IV Lab V 
EU
R
L 
G
EN
 2
.1
 Aminoglycosides aadE 1 in NT NT NT 
Aminoglycosides aph(3’)-III 1 in NT NT NT 
Glycopeptide vanB 1 in NT NT NT 
Macrolides erm(B) 1 in NT NT NT 
Penicillin pbp5 1 in NT NT NT 
Tetracycline tet(L) 1 in NT NT NT 
Tetracycline tet(M) 1 in NT NT NT 
Additional genes detected  tet(K) in NT NT NT 
 
EU
R
L 
G
EN
 2
.2
 Betalactams CTX-M-14 1/NT in 1/1 P 1/NT  1/1 P 
Betalactams OXA-1 1/NT in 1/1 P 1/NT  1/NT P 
Betalactams OXA-30 1/NT in 1/NT P 1/NT  1/1 P 
Chloramphenicol catA1 1 in 1 P 1  1 P 
Quinolones gyrA-83 NT 1/1 P NT 1/1 P 
Quinolones parC-80 NT 1/1 P NT NT 
Streptomycin strA 1 in 1 P 1  1 P 
Streptomycin strB 1 in 1 P 1  1 in 
Streptomycin aadA 1 in 1 P 1  1 P 
Sulfamethoxazole sul2 1 in 1 P 1  1  in 
Tetracycline tetB 1 in 1 P 1  1 P 
Groups detected   CTX-M-9 in       
Table 7: Results from genotypic characterisation.  
Legend: 
1  indicates identification in accordance with the expected  
-  indicates identification not in accordance with the expected 
1/1  indicates ‘correctly identified gene or gene group’/’specific gene or mutation correctly identified’ 
1/-  indicates that the PCR-product was not sequenced to obtain a specific gene- or codon mutation 
NT  indicates ‘Not tested’ 
P indicates that a published PCR-method was used  
in  indicates that an in-house protocol was used 
Laboratory numbers are not consistent with the numbers otherwise used in this report, but they are 
consistent with the number used for the genotypic characterisation in the 2009-iteration. 
 
4. Discussion 
4.1 Salmonella trial  
Overall, the percentage of correct antimicrobial susceptibility test results of Salmonella was 
97.8%. The majority (n=25) of participants obtained satisfactory results according to the level 
of acceptance (<5% deviation). A significant difference (p<0.01) was obtained when 
comparing results obtained by the use of disk diffusion and a MIC method. 
As indicated in Figure 3, the overall quality of the results in the 2010-EQAS would appear to 
be at the same level compared to the performance in the former four iterations.  
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Three (#15, #18, and #40) of the six laboratories exhibiting a deviation level higher than 5% 
performed disk diffusion for AST and obtained deviation levels at 10.3%, 7.7%, and 12.8% , 
respectively. The additional three laboratories (#13, #39 and #41) performed MIC for AST and 
obtained deviation levels at 5.1%, 6.4% and 6.4%, respectively. None of them was defined as 
outlier. 
Ciprofloxacin appeared to cause the majority of the deviations for these six laboratories; for 
laboratory #41, the use of the low cut-off value for ciprofloxacin presented in the protocol 
would have eliminated five deviations and thereby resulted in one deviation only; laboratory 
#18 and #40 failed to record all five Salmonella test strains exhibiting reduced susceptibility to 
ciprofloxacin as resistant. These deviations indicate that the recommendations published by 
Cavaco and Aarestrup (2009) regarding interpretation of ciprofloxacin results could improve 
the quality of the results when performing disk diffusion of AST. In addition, laboratory #40 
did not detect the qnr-positive Salmonella test strain (S-5.6), which was, on the contrary, 
correctly categorised as resistant to ciprofloxacin by laboratory #18. 
For laboratory #15, the deviations neither on the test strain nor on the reference strain allow to 
speculate that a methodical reason should have caused the deviations. Indeed, the ten deviations 
are caused by combinations of seven test strains and six antimicrobials, and the results obtained 
for the E. coli QC reference strain show no deviations on the six antimicrobials in question. 
Also, for laboratory #13, the four deviations could not be attributed to a specific reason. 
Laboratory #39 obtained seven deviations on the test strains but exhibit no deviations for the E. 
coli QC-reference strain. Two of the deviations were due to correct MIC-value being 
interpreted according to other interpretative criteria than those listed in the protocol. The 
additional five deviations are results from testing four different antimicrobials towards the S-
5.2 and S-5.5, and unexpectedly obtaining a conclusion that the strain was resistant.  
The relatively low performance regarding ciprofloxacin presented in Table 2 (90.8% correct 
results), was mainly caused by the three laboratories mentioned above (#18, #40, and #41). One 
additional laboratory (#13) also failed to interpret the obtained MIC value according to the cut-
off value. In addition, when performing disk diffusion, the issue regarding the low cut-off value 
for ciprofloxacin is addressed in the protocol ‘Salmonella strains resistant to nalidixic acid 
should also be interpreted as resistant to ciprofloxacin’. These guidelines appear to have been 
followed by only two of the four laboratories performing disk diffusion.  
The test strain S-5.6 was a Salmonella strain harbouring a plasmid-mediated quinolone 
resistance gene; qnrS. This qnr-gene confers low-level resistance to ciprofloxacin 
(MIC=0.5mg/L), but not to nalidixic acid (MIC=16mg/L). The participants generally found this 
isolate susceptible to nalidixic acid (97%), whereas only 83% found the isolate resistant to 
ciprofloxacin. The reduced susceptibility towards ciprofloxacin resistance caused by a qnr-gene 
is difficult to detect when performing disk diffusion as the usual association between 
ciprofloxacin and nalidixic acid is not seen.  
For the E. coli reference strain, the results obtained were in general in agreement with the CLSI 
recommendations. The number of laboratories performing AST on Salmonella by the use of 
disk diffusion was four. All of these laboratories uploaded data for the testing of the reference 
strain, and a total of 92.3% were within range. For the laboratories performing AST on 
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Salmonella by an MIC-method, all laboratories uploaded QC-results to the database. The 
proportion of values within the expected range was 98.9%.  
Laboratories #15 and #40 which had a deviation level above the acceptance limit in EQAS 
2009 showed values of 5.6% and 7.5% in 2009, respectively, which appear to follow the 
overall trend and have decreased in performance to 10.2% and 12.2% deviations, respectively, 
in the 2010-iteration. 
ESBL-producing Salmonella test strains 
ESBL-producing microorganisms are an emerging problem worldwide, and it should be of a 
high priority for the NRLs to be able to detect them. It was therefore decided at the EURL-AR 
Workshop in June 2008, that the detection of ESBL-producing test strains should be included 
as a mandatory test in this EQAS. 
Two of the Salmonella test strains were ESBL-producers (S-5.7 and S-5.8), and the participants 
were asked to interpret their results according to the description in the protocol. Of the 30 
laboratories which tested Salmonella, two did not upload results for confirmatory testing of 
ESBL-production which resulted in an evaluation as incorrect. The 28 laboratories which 
uploaded results appear to be confident in detecting and confirming the two ESBL-producers 
(S-5.7 and S-5.8) with the overall proportion of laboratories confirming S-5.7 and S-5.8 as 
ESBL-producers being 93% and 90%, respectively. 
Comparison of obtained results when performing confirmatory tests by either of the two 
methods: measurement of inhibition zone diameters (disk diffusion) or by obtaining a MIC-
ratio (E-test) does not show indication of differences for the confirmation on ESBL-production.  
In this EQAS, it appeared that laboratories performing the initial screening with cefotaxime 
only, had problems in the detection of the ESBL production. The two laboratories which are 
registered with incorrect ESBL results for both ESBL-positive strains (#39 and #40) only 
utilized cefotaxime for screening for ESBL production whereas it is recommended that more 
than one cephalosporin is used for the detection of an ESBL-producing Salmonella when 
initially screening the isolate. The cephalosporins cefotaxime, cefpodoxime, ceftiofur, 
ceftriaxone, and ceftazidime were all found useful in detecting isolates with ESBL or plasmidic 
AmpC by Aarestrup et. al. (2010), however, cefotaxime, cefpodoxime, and ceftriaxone were 
superior to the other two.  
Interestingly, both laboratories obtained results that the test strains S-5.7 and S-5.8 were 
resistant towards cefotaxime. This result, however, did not lead to confirmatory testing. 
Laboratory #39 has requested more information and advice on ESBL- detection and 
confirmation which will be part of the follow-up subsequent to this EQAS cycle. In addition, 
laboratory #38 will be contacted for clarification of the absent results.  
4.2 Campylobacter trial  
The overall percentage of correct antimicrobial susceptibility test results of Campylobacter was 
98.0%. The performance varied from no deviations to 11.4% deviations, with 22 laboratories 
performing satisfactorily according to the established acceptance ranges. Of the five 
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laboratories (#19, #21, #22, #30 and #44) with deviation levels above 5%, none were defined as 
outliers.  
The deviation levels above 5% appear to be caused by different reasons: Laboratory #19 
incorrectly detected streptomycin resistance in three of the Campylobacter test strains. No 
reference values are available for streptomycin for the C. jejuni reference strain; for laboratory 
#21, four different test strains combined with four different antimicrobials resulted in five 
deviations. This laboratory did not upload values for the C. jejuni QC reference strain; for 
laboratory #22, the test strain C-5.5 apparently posed a problem, as tests against four of the 
antimicrobials rendered incorrect results. This could be caused by a contamination of the test 
isolate; Laboratories #30 and #44 had deviation levels close to 5% when including results from 
all antimicrobials mentioned in the protocol. Both laboratories had two deviations for 
tetracycline. The result uploaded by laboratory #30 on the reference strain was within range, 
however, on the top limit, whereas laboratory #44 did not upload a value for the reference 
strain on this antimicrobial. In addition, laboratory #44 commented that the two isolates 
incorrectly categorised as resistant to tetracycline, would have been recorded as susceptible, if 
the daily routine method was followed. 
The proportion of results for the C. jejuni reference strain within the QC intervals was 93.2% 
which is the same level as in EQAS 2009. In this year’s trial, 25 of 27 participating laboratories 
uploaded data from tests performed on the reference strain. The eight values outside the QC 
intervals were obtained by six laboratories, five of which performed well under the 5% 
acceptance level. The remaining one had a deviation level at 10% (laboratory #19).  
A follow-up on the laboratory which was an outlier in the Campylobacter trial in EQAS 2009 
(#39) shows a tremendous improvement from a deviation level in 2009 at 25% to 0% in 2010. 
4.3 Optional genotypic characterisation of selected Salmonella test strain 
As the focus on molecular aspects appear to be increasing, it is likely that genotypic 
characterisation of relevant bacterial isolates in the future will gain further interest. The 
genotypic characterisation offered as an optional supplementary part of this EQAS was 
performed by four laboratories. All participating laboratories obtained satisfying results.  
 
5. Conclusions 
The goal of the EURL-AR EQAS is to have all participating NRLs performing antimicrobial 
susceptibility testing of Salmonella and Campylobacter with a deviation level below 5%. This 
seems within reach for Salmonella as well as for Campylobacter.  
The performance of the NRL’s appear to be at the same level for Salmonella AST’s in this 
EQAS (97.8%) when compared to the results from the EQAS 2008 and 2009 (98.0% and 
98.4%). Regarding Campylobacter AST’s, the level of deviation also appears to be stable with 
a level at 2.0% in 2010 compared to 1.3% and 2.2% in 2008 and 2009.  
Laboratories which have not yet introduced tests to detect ESBL-producing 
Enterobacteriaceae, should prioritize this area, as these antimicrobial resistance mechanisms 
appear to continue to emerge worldwide. In addition, the genotypic characterisation which was 
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offered as an optional supplementary part of this EQAS appeared to be of interested to the 
EURL-AR network, and is likely to be repeated. 
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EU Community Reference Laboratory, Antimicrobial Resistance, Kemitorvet, Building 204, DK-2800 Kgs. Lyngby, Denmark 
Ph: + 45 3588 6601, Fax: + 45 3588 6001, e-mail: suska@food.dtu.dk 
 
EURL-AR EQAS pre-notification                                            DFVF- M00-06-001/21.05.2010 
 
EQAS 2010 for Salmonella,  Campylobacter and optional genotypic characterisation 
The EURL-AR are pleased to announce the launch of another EQAS. The EQAS provides the 
opportunity for proficiency testing, which is considered an important tool for the production of 
reliable laboratory results of consistently good quality. 
This EQAS offers antimicrobial susceptibility testing of eight Salmonella isolates, eight 
Campylobacter isolates and two strains for genotypic characterisation (one Shigella and one 
Enterococcus). Additionally, new participants will be offered the following QC strains: E. coli 
ATCC 25922 (CCM 3954) and C. jejuni ATCC 33560 (CCM 6214). 
This EQAS is specifically for NRL’s on antimicrobial resistance. Therefore, you do not need to sign 
up to be a participant. All who receive this pre-notification are automatically regarded as 
participants. Participation is free of charge for all NRL’s.  
TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
Please remember to provide the EQAS coordinator with documents or other information that can 
ease the parcel’s way through customs (eg. specific text that should be written on the invoice). As 
means of avoiding passing the deadline we ask you to send us this information already at this stage. 
For your information, the content of the parcel is “Biological Substance Category B”. The strains 
are expected to arrive at your laboratory in October 2010.  
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol
 
: The isolates will be shipped in October 2010. The protocol will 
be available on the website (www.eurl-ar.eu).  
Returning of results
 
: Results must be returned to the National Food Institute, by December 31st 
2010. When you enter your results via a password-protected website, an evaluation report of your 
results will be generated immediately.  
EQAS report
 
: When the EQAS is concluded, the data will be collected in an overall report in which 
it is possible to see all participants’ results in comparison. In the report the laboratories will be 
coded, which ensures full anonymity; only the National Food Institute and the EU Commission will 
be given access to un-coded results. 
Next EQAS
 
: The next EURL-AR EQAS that we will have is on antimicrobial susceptibility testing 
of E. coli, staphylococci and enterococci which will be carried out in June 2011. 
Any comments regarding the EQAS, please contact me by e-mail (suska@food.dtu.dk) or by 
fax (+45 3588 6341). 
Sincerely, 
 
Susanne Karlsmose 
EQAS-Coordinator 
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Participant list
Salmonella Campylobacter Genotypic characterisation Institute  Country
X X - Austrian Agency for Health and Food Safety Austria
X X - Institute of Public Health Belgium
X - - Nacional Diagnostic and Research Veterinary Institute Bulgaria
X X - Veterinary Services Cyprus
X X - State Veterinary Institute Praha Czech Republic
X X X The National Food Institute Denmark
X - - The National Veterinary Institute Denmark
X X - Estonian Veterinary and Food Laboratory Estonia
X X - Finnish Food Safety Authority EVIRA Finland
X - - ANSES Maisons Alfort France
- X - ANSES Ploufragan France
X X - ANSES Lyon France
X - - ANSES Fougères France
X X X Federal Institute for Risk Assessment Germany
X - - Veterinary Laboratory of Chalkis Greece
X X - Central Agricultural Office, Veterinary Diagnostical Directorate Hungary
- - - University of Iceland Iceland
X X - Central Veterinary Research Laboratory Ireland
X X - Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana Italy
X X - Institute of Food Safety, Animal Health and Environment „BIOR” Latvia
X X - National Veterinary Laboratory Lithuania
X X - Public Health Laboratory Malta
X X - Food and Consumer Product Safety Authority (VWA) Netherlands
X X X Central Veterinary Institute of Wageningen UR Netherlands
X X - Veterinærinstituttet Norway
X X - National Veterinary Research Institute Poland
X X - Laboratorio National de Investigacáo Veterinaria) Portugal
X X - National Institute of Research-Development for Microbiology and 
Immunology “Cantacuzino” 
Romania
X X - Institute for Hygiene and Veterinary Public Health Romania
- - - Institute of Veterinary Medicine of Serbia Serbia
X X - State Veterinary and Food Institute  (SVFI) Slovakia 
X X - National Veterinary Institute Slovenia
- - - Laboratorio Central de Sanidad, Animal de Santa Fe (only Staph) Spain
X X - Laboratorio Central de Sanidad, Animal de Algete Spain
X X - Complutense University of Madrid Spain
X - - Centro nacional de Alimentacion. Agencia Espanola de Seguridad 
Alimentria y Nutricio
Spain
X X - National Veterinary Institute, SVA Sweden
X X - Vetsuisse faculty Bern, Institute of veterinary bacteriology Switzerland
X X - The Veterinary Laboratory Agency United Kingdom
X X X Centre for Infections Health Protection Agency United Kingdom
Designated NRL-AR by the compentent authority of the member state
Non-NRL-AR enroled by the EURL
Not a Member State of the EU
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Salmonella  test strains and reference values (MIC-value and interpretation)
Ampicillin Cefotaxime ESBL-confirmation Ceftazidime ESBL-confirmation Cefoxitin Ceftiofur Chloramphenicol Ciprofloxacin Gentamicin Imipenem Nalidixic acid Streptomycin Sulfamethoxazole Tetracycline Trimethoprim
AMP CTX CTX:CTX/Cl CAZ CAZ:CAZ/Cl XNL CHL CIP GEN IMI NAL STR SMX TET TMP
EURL S-5.1  > 32 RESIST  = 0.25 SUSC  = 0.5 SUSC  = 2 SUSC  > 64 RESIST  = 1 RESIST <= 0.25 SUSC  > 64 RESIST  = 64 RESIST  > 1024 RESIST  > 32 RESIST  > 32 RESIST
EURL S-5.2  > 32 RESIST  = 0.25 SUSC  = 1 SUSC  = 2 SUSC  = 8 SUSC  = 1 RESIST <= 0.25 SUSC  > 64 RESIST  = 32 RESIST  > 1024 RESIST  = 4 SUSC  > 32 RESIST
EURL S-5.3  = 2 SUSC  = 0.25 SUSC  = 0.5 SUSC  = 2 SUSC  = 64 RESIST  = 0.5 RESIST  = 8 RESIST  > 64 RESIST  = 32 RESIST  > 1024 RESIST  > 32 RESIST  > 32 RESIST
EURL S-5.4 <= 1 SUSC <= 0.12 SUSC  = 0.5 SUSC <= 0.5 SUSC  = 4 SUSC  = 0.03 SUSC  = 0.5 SUSC  = 4 SUSC  = 16 SUSC  = 64 SUSC <= 2 SUSC <= 1 SUSC
EURL S-5.5  > 32 RESIST <= 0.12 SUSC  = 0.5 SUSC  = 1 SUSC  = 4 SUSC  = 1 RESIST <= 0.25 SUSC  = 16 SUSC  > 128 RESIST  = 64 SUSC <= 2 SUSC <= 1 SUSC
EURL S-5.6  > 32 RESIST <= 0.12 SUSC  = 0.25 SUSC  = 0.5 SUSC  = 4 SUSC  = 0.5 RESIST  = 1 SUSC  = 16 SUSC  = 16 SUSC  = 32 SUSC <= 2 SUSC <= 1 SUSC
EURL S-5.7  > 32 RESIST > 4 RESIST  >8  = 1 SUSC <8  = 4 SUSC  > 8 RESIST  <= 4 SUSC  = 0.25 RESIST  = 1 SUSC  <= 0.5 SUSC  > 64 RESIST  = 16 SUSC  = 64 SUSC  = 32 RESIST <= 1 SUSC
EURL S-5.8  > 32 RESIST > 4 RESIST  >8  = 128 RESIST  >8  = 4 SUSC  > 8 RESIST  <= 4 SUSC  = 0.03 SUSC  = 1 SUSC  <= 0.5 SUSC  = 4 SUSC  = 16 SUSC  = 64 SUSC <= 2 SUSC <= 1 SUSC
Resistant
Appendix 3b, page 1 of 1
Campylobacter  test strains and reference values (MIC-value and interpretation)
Chloramphenicol Ciprofloxacin Erythromycin Gentamicin Nalidixic acid Streptomycin Tetracycline
Species Code CHL CIP ERY GEN NAL STR TET
C. jejuni EURL C-5.1  = 4 SUSC  = 0.06 SUSC  = 1 SUSC  = 0.25 SUSC  = 4 SUSC  <= 1 SUSC  = 0.12 SUSC
C. coli EURL C-5.2  = 4 SUSC  = 4 RESIST  > 64 RESIST  = 0.25 SUSC  = 64 RESIST  > 16 RESIST  = 16 RESIST
C. coli EURL C-5.3 <= 2 SUSC  = 0.25 SUSC  > 64 RESIST  = 0.25 SUSC  = 8 SUSC  <= 1 SUSC  = 1 SUSC
C. coli EURL C-5.4  = 4 SUSC  = 0.25 SUSC  > 64 RESIST  = 0.5 SUSC  = 8 SUSC  <= 1 SUSC  = 2 SUSC
C. coli EURL C-5.5  = 4 SUSC  = 4 RESIST  = 0.5 SUSC  = 0.25 SUSC  = 64 RESIST  > 16 RESIST  = 0.25 SUSC
C. coli EURL C-5.6  = 4 SUSC  = 0.25 SUSC  > 64 RESIST  = 0.25 SUSC  = 8 SUSC  <= 1 SUSC  > 64 RESIST
C. jejuni EURL C-5.7 <= 2 SUSC  = 0.12 SUSC  = 1 SUSC  = 0.25 SUSC  = 4 SUSC  <= 1 SUSC  = 64 RESIST
C. jejuni EURL C-5.8 <= 2 SUSC  = 16 RESIST  = 2 SUSC  = 0.25 SUSC  > 64 RESIST  <= 1 SUSC  > 64 RESIST
Resistant
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EURL-AR External Quality Assurance System 2010 
- Salmonella, Campylobacter and optional genotypic characterisation  
 
Id: >>Id<< 
>>Institute<< 
>>Country<< 
Kgs. Lyngby, October 2010 
Dear >>name<<, 
 
Please find enclosed the bacterial strains for the EURL-AR EQAS 2010.  
 
On the EURL-AR-website (www.eurl-ar.eu) the following documents relevant for the EURL-AR 
EQAS are available: 
- Protocol for Salmonella and Campylobacter including test forms 
- Instructions for Opening and Reviving Lyophilised Cultures 
- Subculture and Maintenance of Quality Strains 
 
We ask you to examine the eight Salmonella and the eight Campylobacter strains that we send to 
you by performing antimicrobial susceptibility testing. The additional strains (EURL GEN 2.1 and 
EURL GEN 2.2) are included for optional genotypic characterisation. In the protocol you will find 
detailed description of how to test the strains. Additionally, you will find a description of how to 
enter your results into the interactive web database. For entering data you need this username and 
password. 
 
 
Your username: >>username<< 
Your password: >>password<< 
 
Please keep this document 
  Your username and password will not appear in other documents 
 
 
After receipt, the strains should be stored dark and at 4°C for stabs, and dark and cool for freeze-
dried strains. Charcoal swabs must be subcultured straight away.  
 
The results should be returned to us no later than December 31st
 
, 2010. 
Please acknowledge receipt of parcel immediately on arrival (by email to suska@food.dtu.dk). For 
further information, please do not hesitate to contact us. 
 
Yours sincerely, 
 
Susanne Karlsmose 
EQAS-Coordinator 
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2010 
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PROTOCOL  
For susceptibility testing of Salmonella, Campylobacter and optional genotypic 
characterisation of two test strains 
 
 
1   INTRODUCTION    ................................................................................................................. 1
2   OBJECTIVES    ....................................................................................................................... 2
3   OUTLINE OF THE EQAS 2010    ......................................................................................... 2
3.1   Shipping, receipt and storage of strains    ............................................................... 2
3.2   Suggested procedure for reconstitution of the lyophilised reference strains    .... 2
3.3   Susceptibility testing    .............................................................................................. 2
3.4   Optional genotypic characterisation    ..................................................................... 5
4   REPORTING OF RESULTS AND EVALUATION    ......................................................... 7
5   HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE    .......................... 8
 
 
1 INTRODUCTION 
One of the tasks as the EU Reference Laboratory for Antimicrobial Resistance (EURL-AR) is to 
organise and conduct an External Quality Assurance System (EQAS) on susceptibility testing of 
Salmonella and Campylobacter. The Salmonella and Campylobacter EQAS 2010 will include 
susceptibility testing of eight Salmonella and eight Campylobacter strains together with 
susceptibility testing of the reference strains E. coli ATCC 25922 (CCM 3954) and C. jejuni ATCC 
33560 (CCM 6214). Additionally, optional PCR-testing of a selected Gram-negative isolate and a 
selected Gram-positive isolate is offered. 
For new participants of the EQAS who have not already received the mentioned reference strains, 
these are included in the parcel. The reference strains will not be included in the years to come. The 
reference strains are original certified cultures and are free of charge. Please take proper care of the 
strains. Handle and maintain them as suggested in the manual ‘Subculture and Maintenance of QC 
Strains’. Please use them for future internal quality control for susceptibility testing in your 
laboratory.  
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Various aspects of the proficiency test scheme may from time to time be subcontracted. When 
subcontracting occurs it is placed with a competent subcontractor and the National Food Institute is 
responsible to the scheme participants for the subcontractor’s work. 
2 OBJECTIVES 
The main objective of this EQAS is to support laboratories to assess and if necessary improve the 
quality of susceptibility testing of pathogens originating from food and animal sources, especially 
Salmonella and Campylobacter. Furthermore, to assess and improve the comparability of 
surveillance and antimicrobial susceptibility data reported to EFSA by different laboratories on 
Salmonella and Campylobacter and to harmonise the breakpoints used within the EU. 
3 OUTLINE OF THE EQAS 2010 
3.2 3.1    Shipping, receipt and storage of strains 
In October 2010, the EU appointed National Reference Laboratories will receive a parcel from the 
National Food Institute containing eight Salmonella, eight Campylobacter strains and 2 additional 
strain(s) for optional PCR (one Shigella and one Entercoccus). Reference strains will be included 
for participants who have not previously received these. All strains are non-toxin producing human 
pathogens Class II. There might be ESBL-producing strains among the selected material.  
The reference strains are shipped lyophilised, the Campylobacter test strains are shipped as a 
charcoal swabs and the Salmonella test strains are stab cultures. On arrival, the stab cultures and the 
charcoal swabs must be subcultured, and all cultures should be kept refrigerated until testing. A 
suggested procedure for reconstitution of the lyophilised reference strains is presented below. 
3.3 Suggested procedure for reconstitution of the lyophilised reference strains  
Please see the document ‘Instructions for opening and reviving lyophilised cultures’ on the EURL-
AR-website (see www.eurl-ar.eu). 
3.4 Susceptibility testing 
The strains should be susceptibility tested towards as many as possible of the following 
antimicrobials by the method used in the laboratory when performing monitoring for EFSA
Participants using disk diffusion are recommended to interpret the results according to their 
individual breakpoints, categorising them into the terms resistant and sensitive. A categorization as 
intermediary is not accepted; therefore intermediary results should be interpreted as susceptible. 
. For 
MIC the cut off values listed in tables 3.3.1 and 3.3.2 should be used. The epidemiological cut-off 
values allow two categories of characterisation – resistant or sensitive.  
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Interpretations in concordance with the expected value will be categorised as ‘correct’, whereas 
interpretations that deviate from the expected interpretation will be categorised as ‘incorrect’.  
The cut off values used in the interpretation of the MIC results are developed by EUCAST 
(www.eucast.org). 
With regard to MIC range and/or disc content we ask you to fill in these pieces of information in the 
database. Also, if you do not use
 
 the cut-off values listed in the protocol for interpretation of the 
susceptibility results, please fill in or update the breakpoints used, in the database. 
3.4.1 Salmonella. 
Testing of gentamicin and streptomycin
Also, when following EUCAST epidemiological cut-off values, Salmonella resistant to 
 may be of value for monitoring. Please, do not take into 
account in this study, that the CLSI guidelines state that for aminoglycosides Salmonella should not 
be reported as susceptible. 
nalidixic 
acid should also be interpreted as resistant to ciprofloxacin
Antimicrobials for Salmonella 
. When using disc diffusion and CLSI 
clinical breakpoints this connection between nalidixic acid and ciprofloxacin is not taken into 
account. Thus, the result in this situation with regard to ciprofloxacin will deviate from the expected 
result in this EQAS. 
MIC (µg/mL) 
R is > 
Ampicillin (AMP) 8 
Cefotaxime (CTX) 0,5 
Ceftazidime (CAZ)** 2 
Ceftiofur (XNL)** 2 
Chloramphenicol (CHL) 16 
Ciprofloxacin (CIP) 0.06 
Gentamicin (GEN) 2 
Nalidixic acid (NAL) 16 
Streptomycin (STR) 16 
Sulphonamides (SMX)* 256 
Tetracycline (TET) 8 
Trimethoprim (TMP) 2 
Table 1: Interpretative guidelines for Salmonella  
* CLSI     
** Not part of the EFSA monitoring programme (used for confirmatory tests for ESBL production) 
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The following tests regarding ESBL production are mandatory: All strains resistant against 
cefotaxime (CTX), ceftazidime (CAZ) or ceftiofur (XNL) should be confirmed by confirmatory 
tests for ESBL production. 
ESBL production 
The confirmatory tests for ESBL production require testing with a pure antimicrobial (CTX and 
CAZ) vs. a test with the same antimicrobial combined with a β-lactamase inhibitor (clavulanic 
acid). Synergy is defined as a 3 dilution steps difference between the two compounds in at least one 
of the two cases (MIC ratio ≥ 8, E-test 3 dilution steps) or an increase in zone diameter ≥ 5 mm 
(CLSI M100 Table 2A; enterobacteriaceae). If the test shows signs of synergy it is an indication of 
the presence of ESBL.  
Confirmatory tests for Metallo beta lactamase require comparison between imipenem (IMI) and 
IMI/EDTA, synergy is in this test defined as a MIC ratio ≥ 8 or E-test 3 dilution steps difference 
(CLSI M100 Table 2A; enterobacteriaceae). If the test shows signs of synergy it is an indication of 
the presence of ESBL.  
Additionally, AmpC detection can be performed by testing the microorganism to cefoxitin (FOX), 
resistance to FOX could indicate AmpC. Verification of AmpC requires PCR or sequencing. 
The EURL-AR aim to harmonize with EUCAST expert rules. .Concerning cefotaxime, ceftazidime 
and/or ceftiofur used when detecting ESBL-producing strains in this EQAS, MIC values and 
interpretations for these antimicrobials should be reported as found. . 
 
3.4.2 Campylobacter   
Antimicrobials for Campylobacter MIC (µg/mL) 
R is > 
MIC (µg/mL) 
R is > 
 C. jejuni C. coli 
Chloramphenicol* 16 16 
Ciprofloxacin 1 1 
Erythromycin 4 16 
Gentamicin 1 2 
Nalicixic acid* 16 32 
Streptomycin 2 4 
Tetracycline 2 2 
Table 2: Interpretative guidelines for Campylobacter  
*Not part of the EFSA monitoring programme 
  
 
Please find information on the test forms showing which test strains are C. jejuni and C. coli 
respectively. 
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The sub-cultured Campylobacter should be used for the MIC-testing after incubation at 36-37ºC for 
48 hours or 42ºC for 24 hours.  
3.5 Optional genotypic characterisation 
An optional PCR-testing of a selected E. faecium (EURL GEN 2.1) as well as a Shigella (EURL 
GEN 2.2) isolate is offered. If performing the genotypic characterisation of these test strains, the 
results requested are the genes harboured in the test strain. The genes listed in Tables 3 and 4 below 
are those included in the test. The test strains may harbour resistance genes not present on these 
lists; these will not be evaluated by the database, but may be mentioned in the comments-field. 
When uploading the results in the database, the identified genes will be evaluated against the 
expected results. The results will be evaluated on the actual gene identified. The groups of TEM-, 
CTX-, SHV-, CMY-, OXA-genes as well as the gyrA-mutations and parC-mutations will 
additionally be evaluated on the group selected. For gyrA and parC the codon-no of the site of 
mutation will be evaluated in the same way as the genes. 
The method used for the PCR-testing should be the one(s) used in your laboratory. The expected 
results listed in the database are those obtained by the CRL (as this is a pilot study the results have 
not been verified elsewhere).  
 
Antimicrobial Gene 
Aminoglycosides aadE 
 aac(6’)-aph(2”) 
 aph(3’)-III 
Chloramphenicol catpIP 
Glycopeptide vanA 
 vanB 
Macrolides erm(A) 
 erm(B) 
Oligosaccharides emtA 
Penicillin pbp5 
Streptogramin A vat(D) 
 vat(E) 
Streptogramin B vgbA 
Tetracycline tet(K) 
 tet(L) 
 tet(M) 
 tet(O) 
 tet(S) 
Table 3: Genes included in the test of the E. faecium-strain 
Reference: Simjee, S. et al. Enterococcus (2006). In: Frank M. Aarestrup (Ed.) 
Antimicrobial Resistance in Bacteria of Animal Origin, ASM Press, Washington, D.C., 
pp. 315-328. 
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Antimicrobial Group Gene/Codon no. 
Betalactams TEM List of gene numbers in the database 
 CTX List of gene numbers in the database 
 SHV List of gene numbers in the database 
 CMY List of gene numbers in the database 
 OXA List of gene numbers in the database 
Chloramphenicol - cmlA 
 - catA1 
Florphenicol - floR 
Gentamicin - aac(3)-IV 
 - ant(2")-I 
 - aac(3)-II 
Neomycin - aph(3’)-III 
 - aph(3’)-II 
 - aph(3’)-I 
Quinolones gyrA Codon 83 
 gyrA Codon 87 
 parC Codon 57 
 parC Codon 78 
 parC Codon 80 
 parC Codon 84 
 - qnrA 
 - qnrB 
 - qnrC 
 - qnrD 
 - qnrS 
Streptomycin - strA 
 - strB 
 - aadA 
Sulfamethoxazole - sul1 
 - sul2 
 - sul3 
Tetracycline - tetA 
 - tetB 
 - tetC 
 - tetD 
 - tetE 
 - tetF 
 - tetG 
Table 4: Genes included in the test of the Shigella-strain 
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4 REPORTING OF RESULTS AND EVALUATION 
Fill in your results in the test forms, and enter your results into the interactive web database. Please 
read the detailed description below before entering your results. When you enter the results via the 
web, you will be guided through all steps on the screen and you will immediately be able to view 
and print an evaluation report of your results. Please submit results by latest December 31st
If you do not have access to the Internet, or if you experience difficulties entering the data, please 
return results by e-mail, fax or mail to the National Food Institute.  
, 2010.  
All results will be summarized in a report which will be made available to all participants. The data 
in the report will be presented with laboratory codes. A laboratory code is known to the individual 
laboratory, whereas the entire list of laboratories and their codes is confidential and known only to 
the EURL and the EU Commission. All conclusions are public. 
If you have any questions, please do not hesitate to contact the EQAS Coordinator: 
 
Susanne Karlsmose 
National Food Institute 
Technical University of Denmark 
Kemitorvet, Building 204, DK-2800 Lyngby 
Denmark 
Tel: +45 3588 6601 
Fax: +45 3588 6341 
E-mail: suska@food.dtu.dk 
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5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read this passage before entering the web page. Before you go ahead, you need your test form 
by your side together with your breakpoint values.  
You are able to browse back and forth by using the forward and back keys or click on the EURL 
logo. 
You enter the EURL-AR EQAS 2010 start web page (http://thor.dfvf.dk/crl) then write your 
username and password in low cases and press enter. Your username and password is the same as in 
the previous EQAS’s arranged by the National Food Institute. If you have problems with the login 
please contact us. 
Click on either “Salmonella test results” or “Campylobacter test results” depending on your results. 
The below description is aimed at Salmonella entry but is exactly the same as for Campylobacter 
entry. 
Click on "Start of Data Entry - Methods and Breakpoints for Salm.” 
In the next page you navigate to fields with the Tab-key and mouse.  
Fill in what kind of method you have used for the susceptibility testing of Salmonella and the brand 
of discs, tablets, MIC trays etc.  
Fill in the relevant information, either disk content or MIC range. If you use disk diffusion, please 
upload the breakpoints used. 
You will find one more box to fill in on this page when testing Campylobacter: Fill in the actual 
incubation condition used for susceptibility testing of Campylobacter – 36°C/48h or 42°C/24h. 
Click on "save and go to next page”  
In the data entry pages for each Salmonella and Campylobacter strain, you enter the obtained value 
and the interpretation as R or S. 
For Salmonella, you also type in results for the ESBL tests. 
If you have not used an antimicrobial, please leave the field empty. 
Click on "save and go to next page" 
When uploading data on the reference strains please enter the zonediameters in mm or MIC values 
in µg/ml. Remember to use the operator keys to show e.g. equal to, etc. If you do not use CLSI 
guidelines for AST on the reference strains, please add a comment on the method used. 
Click on "save and go to next page" 
This page is a menu, from where you can review the input pages, approve your input and finally see 
and print the evaluated results: 
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Browse through the pages and make corrections if necessary. Remember to save a page if you make 
any corrections. If you save a page without changes, you will see an error screen, and you just have 
to click on "back" to get back to the page and "go to next page" to continue. 
Please fill in the evaluation form. 
Approve your input. Be sure that you have filled in all the results before approval, as  YOU CAN 
ONLY APPROVE ONCE!  The approval blocks your data entry in the interactive database, but 
allows you to see the evaluated results.   
If you have performed the optional genotypic characterisation: 
Click on “Gene test” and follow the description in the database for upload of the optional PCR 
results. Approve your input. Be sure that you have filled in all the results before approval. The 
approval blocks your data entry in the interactive database, but allows you to see the evaluated 
results. 
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Salmonella and Campylobacter, genetic characterisation 
 
TEST FORMS 
   
 
 
Name:       
 
Name of laboratory:       
 
Name of institute:       
 
City:       
 
Country:       
 
E-mail:       
 
Fax:       
 
 
Comments:       
EU Community Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2010 
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TEST FORM                                                            
 
Which method did you use for antimicrobial susceptibility testing of Salmonella in this EQAS: 
  MIC – Microtitre    
  MIC – Agar dilution 
  Strips – E-test                                       
  Discs, tablets     
  Rosco, Neo Sensitabs  
 Brand:                            
 
How many Salmonella isolates does your laboratory annually isolate:       
How many Salmonella isolates does your laboratory annually susceptibility test:       
Comments or additional information:       
 
 
 
 
 
Antimicrobial  General info 
 
The relevant information in the 
two columns below should be 
filled in 
 
Zonediameter (mm) 
 
Please, only fill in breakpoint information if 
you did not use the cut-off values listed in 
the protocol  
 
Disk content 
(μg) 
Test-range for 
MIC 
(μg/mL) 
Resistant 
(mm) 
Intermediate 
(mm) 
Sensitive 
(mm) 
 
Ampicillin, AMP             ≤             ≥       
Cefotaxime, CTX             ≤             ≥       
Ceftazidime, CAZ             ≤             ≥       
Ceftiofur, XNL             ≤             ≥       
Chloramphenicol, CHL             ≤             ≥       
Ciprofloxacin, CIP             ≤             ≥       
Gentamicin, GEN             ≤             ≥       
Nalidixic acid, NAL             ≤             ≥       
Streptomycin, STR             ≤             ≥       
Sulphamethoxazole, SMX             ≤             ≥       
Tetracycline, TET             ≤             ≥       
Trimethoprim, TMP               ≤             ≥       
EU Community Reference Laboratory for Antimicrobial Resistance  
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TEST FORM                                                            
 
Which method did you use for antimicrobial susceptibility testing of Campylobacter in this EQAS: 
  MIC – Microtitre    
  MIC – Agar dilution 
  Strips – E-test                                       
  Discs, tablets     
  Rosco, Neo Sensitabs  
 Brand:                 
 Incubation conditions:      °C/     h 
            
 
How many Campylobacter isolates does your laboratory annually isolate:       
How many Campylobacter isolates does your laboratory annually susceptibility test:       
Comments or additional information:       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antimicrobial  General info 
 
The relevant information 
should be filled in below 
 
Test-range for MIC 
(μg/mL) 
Chloramphenicol       
Ciprofloxacin       
Erythromycin       
Gentamicin       
Nalidixic Acid       
Streptomycin       
Tetracycline       
EU Community Reference Laboratory for Antimicrobial Resistance  
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TEST FORM  
Strain  
 
 
Antimicrobial  
Interpretation 
 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Salmonella 
EURL S-5.X 
 
 
Ampicillin, AMP     
  
         
   Cefotaxime, CTX     
  
         
   Ceftazidime, CAZ     
  
         
   Ceftiofur, XNL     
  
         
   Chloramphenicol, CHL     
  
         
   Ciprofloxacin, CIP     
  
         
   Gentamicin, GEN     
  
         
   Nalidixic acid, NAL     
  
         
   Streptomycin, STR     
  
         
   Sulfonamides, SMX     
  
         
   Tetracycline, TET     
  
         
   Trimethoprim, TMP     
  
         
    
All strains resistant against cefotaxime (CTX), ceftazidime (CAZ) or ceftiofur (XNL) should be 
included for confirmatory tests for ESBL production.  
See further description of confirmatory tests above in section ‘3.3.1 Salmonella’. 
 MIC, value or ratio  Disks, zone diameter or increase 
CTX/CL : CTX mic ratio    
 MIC ratio ≥ 8 (synergy) 
 MIC ratio < 8 
 Phantom zone (synergy) 
 Deformation (synergy) 
 Not determinable 
 Incr. in zone diam   
 Incr. ≥ 5 mm (synergy) 
 Incr.< 5 mm 
 
CAZ/CL : CAZ mic ratio  
 MIC ratio ≥ 8 (synergy) 
 MIC ratio < 8 
 Phantom zone (synergy) 
 Deformation (synergy) 
 Not determinable 
 Incr. in zone diam  
 Incr. ≥ 5 mm (synergy) 
 Incr.< 5 mm 
 
Cefoxitin, FOX mic value   MIC value > 16   MIC value ≤ 16  Zone diameter  
 D ≤ 14 mm  
 D > 14 mm 
Imipenem, IMI mic value   MIC value > 1   MIC value ≤ 1 
 Confirmed ESBL 
 Confirmed AmpC 
 Confirmed Metallo betalactamase IMI/E : IMI mic ratio  
 MIC ratio ≥ 8 (synergy) 
 MIC ratio < 8 
 Phantom zone (synergy) 
 Deformation (synergy) 
 Not determinable 
Comments:       
EU Community Reference Laboratory for Antimicrobial Resistance  
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TEST FORM                                                            
 
Susceptibility testing of E. coli referencestrain ATCC 25922 
 
Strain 
 
 
 
Antimicrobial  
 
Zonediameter (mm) or  
MIC-value (μg/ml) 
E. coli ATCC 25922 
 
 
 
 
Ampicillin, AMP       
Cefotaxime, CTX       
Cefoxitin, FOX       
Ceftazidime, CAZ       
Ceftiofur, XNL       
Chloramphenicol, CHL       
Ciprofloxacin, CIP       
Gentamicin, GEN       
Imipenem, IMI       
Nalidixic acid, NAL       
Streptomycin, STR       
Sulfisoxazole, FIS*       
Tetracycline, TET       
Trimethoprim, TMP       
 
*The antimicrobial which is mentioned in the CLSI M100 performance standard as a representative 
for the sulfonamides as regards acceptable limits for quality control strains (CLSI M100, Table 3) 
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TEST FORM                                                           
Strain Antimicrobial  Interpretation 
MIC-value (μg/ml) S / R 
Campylobacter 
EURL C-5.1 
 
C. jejuni 
 
Chloramphenicol             
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic Acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C-5.2 
 
C. coli 
Chloramphenicol             
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic Acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C-5.3 
 
C. coli 
Chloramphenicol             
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic Acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C-5.4 
 
C. coli 
Chloramphenicol             
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic Acid             
Streptomycin             
Tetracycline             
EU Community Reference Laboratory for Antimicrobial Resistance  
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TEST FORM                                                            
Strain Antimicrobial  Interpretation 
MIC-value (μg/ml) S / R 
Campylobacter 
EURL C-5.5 
 
C. coli 
Chloramphenicol   
Ciprofloxacin   
Erythromycin   
Gentamicin   
Nalidixic Acid   
Streptomycin   
Tetracycline   
Campylobacter 
EURL C-5.6 
 
C. coli 
Chloramphenicol   
Ciprofloxacin   
Erythromycin   
Gentamicin   
Nalidixic Acid   
Streptomycin   
Tetracycline   
Campylobacter 
EURL C-5.7 
 
C. jejuni 
 
Chloramphenicol   
Ciprofloxacin   
Erythromycin   
Gentamicin   
Nalidixic Acid   
Streptomycin   
Tetracycline   
Campylobacter 
EURL C-5.8 
 
C. jejuni 
 
Chloramphenicol   
Ciprofloxacin   
Erythromycin   
Gentamicin   
Nalidixic Acid   
Streptomycin   
Tetracycline   
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TEST FORM                                                           
 
Susceptibility testing of Campylobacter jejuni reference strain ATCC 33560 
 
Strain 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
36 °C/48 hours 
 
42 °C/24 hours 
 
 
C. jejuni ATCC 33560 
 
Chloramphenicol             
Ciprofloxacin             
Erythromycin             
Nalidixic Acid             
Tetracycline             
 
 
  
For Agar dilution: 
 
 Susceptibility testing of Campylobacter jejuni reference strain ATCC 33560 
 
Strain 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
 
C. jejuni ATCC 33560 
 
 
Ciprofloxacin       
 
Doxycycline        
 
Erythromycin        
 
Gentamicin       
Meropenem        
Nalidixic Acid        
Tetracycline       
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TEST FORM – genotypic characterisation                                                           
 
Genotypic characterisation of the test strains 
 
EURL GEN 2.X PCR-method used 
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
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INSTRUCTIONS FOR OPENING AND REVIVING 
LYOPHILISED CULTURES 
 
 
Manual from  Czech Collection of Microorganisms (CCM) 
 Masaryk University 
 Tvrdého 14 
 602 00 BRNO 
 Czech Republic 
 
Lyophilised cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule. All instructions given below should be followed closely to ensure the safety of the person 
who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture on the label inside the ampoule 
b. Make a file cut on the ampoule near the middle of the plug 
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool from 
just below the plug to the pointed end 
d. Apply a red-hot glass rod to the file cut to crack the glass and allow air to enter slowly into 
the ampoule 
e. Remove the pointed end of the ampoule into disinfectant 
f. Add about 0.3 ml appropriate broth to the dried suspension using a sterile Pasteur pipette 
and mix carefully to avoid creating aerosols. Transfer the contents to one or more suitable 
solid and /or liquid media 
g. Incubate the inoculated medium at appropriate conditions for several days 
h. Autoclave or disinfect effectively the used Pasteur pipette, the plug and all the remains of 
the original ampoule before discarding 
Please note that:  
 Cultures should be grown on media and under conditions as recommended in the CCM 
catalogue 
 Cultures may need at least one subculturing before they can be optimally used in experiments 
 Unopened ampoules should be kept in a dark and cool place! 
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SUBCULTURE AND MAINTENANCE OF    
QUALITY CONTROL STRAINS 
1.1 Purpose 
Improper storage and repeated subculturing of bacteria can produce alterations in antimicrobial 
susceptibility test results. The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) 
has published a guideline for Quality Control (QC) stock culture maintenance to ensure consistent 
antimicrobial susceptibility test results. 
1.2 References 
M100-S18, January 2008 (Performance Standards for Antimicrobial Susceptibility Testing) 
M7-A7, January 2006 (Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That 
Grow Aerobically; Approved Standard) 
1.3 Definition of Terms 
Reference Culture: A reference culture is a microorganism preparation that is acquired from a 
culture type collection.  
Reference Stock Culture: A reference stock culture is a microorganism preparation that is derived 
from a reference culture. Guidelines and standards outline how reference stock cultures must be 
processed and stored.  
Working Stock Cultures: A working stock culture is growth derived from a reference stock culture. 
Guidelines and standards outline how working stock cultures must be processed and how often they 
can be subcultured.  
Subcultures (Passages): A subculture is simply the transfer of established microorganism growth on 
media to fresh media. The subsequent growth on the fresh media constitutes a subculture or 
passage. Growing a reference culture or reference stock culture from its preserved status (frozen or 
lyophilized) is not a subculture. The preserved microorganism is not in a stage of established 
growth until it is thawed or hydrated and grown for the first time 
1.4 Important Considerations 
 Do not use disc diffusion strains for MIC determination. 
 Obtain QC strains from a reliable source such as ATCC 
 CLSI requires that QC be performed either on the same day or weekly (only after 30 day QC 
validation) 
 Any changes in materials or procedure must be validated with QC before implemented 
 For example: Agar and broth methods may give different QC ranges for drugs such as 
glycopeptides, aminoglycosides and macrolides 
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 Periodically perform colony counts to check the inoculum preparation procedure 
 Ideally, test values should be in the middle of the acceptable range 
 Graphing QC data points over time can help identify changes in data helpful for 
troubleshooting problems 
1.5 Storage of Reference Strains 
Preparation of stock cultures 
 Use a suitable stabilizer such as 50% fecal calf serum in broth, 10-15% glycerol in tryptic 
soy broth, defibrinated sheep blood or skim milk to prepare multiple aliquots. 
 Store at -20°C, -70°C or liquid nitrogen. (Alternatively, freeze dry.) 
 Before using rejuvenated strains for QC, subculture to check for purity and viability. 
Working cultures 
 Set up on agar slants with appropriate medium, store at 4-8°C and subculture weekly. 
 Replace the working strain with a stock culture at least monthly. 
 If a change in the organisms inherent susceptibility occurs, obtain a fresh stock culture or a 
new strain from a reference culture collection e.g. ATCC. 
1.6 Frequency of Testing 
Weekly vs. daily testing  
Weekly testing is possible if the lab can demonstrate satisfactory performance with daily testing as 
follows: 
 Documentation showing reference strain results from 30 consecutive test days were within 
the acceptable range. 
 For each antimicrobial/organism combination, no more than 3 out of 30 MIC values may be 
outside the acceptable range. 
When the above are fulfilled, each quality control strain may be tested once a week and whenever 
any reagent component is changed. 
Corrective Actions  
If an MIC is outside the range in weekly testing, corrective action is required as follows: 
 Repeat the test if there is an obvious error e.g. wrong strain or incubation conditions used 
 If there is no obvious error, return to daily control testing 
The problem is considered resolved only after the reference strain is tested for 5 consecutive days 
and each drug/organism result is within specification on each day. 
If the problem cannot be resolved, continue daily testing until the errors are identified. 
Repeat the 30 days validation before resuming weekly testing. 
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Disk content and breakpoints used in daily routine (disk diffusion) - Salmonella
Antimicrobial Lab No Disk content 
(ug)
R <= (mm) I  = (mm) S >= (mm)
Ampicillin, AMP 15 25 13 14-20 21
Ampicillin, AMP 18 10 13 14-16 17
Ampicillin, AMP 38 10 13 14-16 17
Ampicillin, AMP 40 10 13 14-16 17
Cefotaxime, CTX 15 30 22 23-25 26
Cefotaxime, CTX 18 30 22 23-25 26
Cefotaxime, CTX 38 30 22 23-25 26
Cefotaxime, CTX 40 30 14 15-22 23
Ceftazidime, CAZ 15 30 18 19-25 26
Ceftazidime, CAZ 18 30 17 18-20 21
Ceftazidime, CAZ 40 30 14 15-17 18
Ceftiofur, XNL 15 30 17 18-20 21
Ceftiofur, XNL 18 30
Ceftiofur, XNL 40 30 14
Chloramphenicol, CHL 15 30 18 19-21 22
Chloramphenicol, CHL 18 30 12 13-17 18
Chloramphenicol, CHL 38 30 12 13-17 18
Chloramphenicol, CHL 40 30 12 13-17 18
Ciprofloxacin, CIP 15 16 17-21 22
Ciprofloxacin, CIP 18 5 15 16-20 21
Ciprofloxacin, CIP 38 5 15 16-20 21
Ciprofloxacin, CIP 40 5 15 16-20 21
Gentamicin, GEN 15 15 15 16-17 18
Gentamicin, GEN 18 10 12 13-14 15
Gentamicin, GEN 38 10 12 13-14 15
Gentamicin, GEN 40 10 12 13-14 15
Nalidixic acid, NAL 15 30 14 15-19 20
Nalidixic acid, NAL 18 30 13 14-18 19
Nalidixic acid, NAL 38 30 13 14-18 19
Nalidixic acid, NAL 40 30 13 14-18 19
Streptomycin, STR 15 10  UI 12 13-14 15
Streptomycin, STR 18 10 11 12-14 15
Streptomycin, STR 38 10 11 12-14 15
Streptomycin, STR 40 10 11 12-14 15
Sulfamethoxazole, SMX 15 200 11 12-16 17
Sulfamethoxazole, SMX 18 300 12 13-16 17
Sulfamethoxazole, SMX 40 300 12 13-16 17
Tetracycline,TET 15 30 UI 16 17-18 19
Tetracycline,TET 18 30 11 12-14 15
Tetracycline,TET 38 30 11 12-14 15
Tetracycline,TET 40 30 11 12-14 15
Trimethoprim, TMP 15 5 11 12-15 16
Trimethoprim, TMP 18 5 10 11-15 16
Trimethoprim, TMP 38 5 10 11-15 16
Trimethoprim, TMP 40 5 10 11-15 16
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Test results from the reference strain E. coli ATCC 25922
Lab no. Antimicrobial Operator Value Low limit High limit Mark Method
1 Ampicillin, AMP = 4 2 8 1 MIC
1 Cefotaxime, CTX <= 0.125 0,03 0,125 1 MIC
1 Ceftiofur, XNL <= 0.5 0,25 1 1 MIC
1 Chloramphenicol, CHL = 4 2 8 1 MIC
1 Ciprofloxacin, CIP <= 0.015 0,004 0,016 1 MIC
1 Gentamicin, GEN = 1 0,25 1 1 MIC
1 Nalidixic acid, NAL <= 4 1 4 1 MIC
1 Streptomycin, STR <= 8 4 16 1 MIC
1 Tetracycline, TET <= 2 0,5 2 1 MIC
1 Trimethoprim, TMP <= 1 0,5 2 1 MIC
2 Ampicillin, AMP = 4 2 8 1 MIC
2 Cefotaxime, CTX <= 0.06 0,03 0,125 1 MIC
2 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
2 Chloramphenicol, CHL = 4 2 8 1 MIC
2 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
2 Gentamicin, GEN = 0.5 0,25 1 1 MIC
2 Nalidixic acid, NAL <= 4 1 4 1 MIC
2 Streptomycin, STR = 8 4 16 1 MIC
2 Sulfisoxazole, FIS = 32 8 32 1 MIC
2 Tetracycline, TET <= 1 0,5 2 1 MIC
2 Trimethoprim, TMP <= 0.5 0,5 2 1 MIC
4 Ampicillin, AMP = 4 2 8 1 MIC
4 Cefotaxime, CTX = 0.06 0,03 0,125 1 MIC
4 Ceftazidime, CAZ = 0.25 0,06 0,5 1 MIC
4 Chloramphenicol, CHL = 4 2 8 1 MIC
4 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
4 Gentamicin, GEN = 1 0,25 1 1 MIC
4 Nalidixic acid, NAL = 4 1 4 1 MIC
4 Streptomycin, STR = 8 4 16 1 MIC
4 Sulfisoxazole, FIS = 32 8 32 1 MIC
4 Tetracycline, TET = 1 0,5 2 1 MIC
4 Trimethoprim, TMP = 1 0,5 2 1 MIC
6 Ampicillin, AMP = 4 2 8 1 MIC
6 Cefotaxime, CTX <= 0.06 0,03 0,125 1 MIC
6 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
6 Chloramphenicol, CHL = 4 2 8 1 MIC
6 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
6 Gentamicin, GEN = 0.5 0,25 1 1 MIC
6 Nalidixic acid, NAL <= 4 1 4 1 MIC
6 Streptomycin, STR = 8 4 16 1 MIC
6 Tetracycline, TET <= 1 0,5 2 1 MIC
6 Trimethoprim, TMP <= 0.5 0,5 2 1 MIC
9 Ampicillin, AMP = 4 2 8 1 MIC
9 Cefotaxime, CTX = 0.12 0,03 0,125 1 MIC
9 Cefoxitin, FOX = 4 2 8 1 MIC
9 Ceftazidime, CAZ = 0.25 0,06 0,5 1 MIC
9 Chloramphenicol, CHL = 4 2 8 1 MIC
9 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
9 Gentamicin, GEN = 0.5 0,25 1 1 MIC
9 Imipenem, IMI = 0.12 0,06 0,25 1 MIC
9 Nalidixic acid, NAL <= 4 1 4 1 MIC
9 Streptomycin, STR = 8 4 16 1 MIC
9 Sulfisoxazole, FIS = 16 8 32 1 MIC
9 Tetracycline, TET = 1 0,5 2 1 MIC
9 Trimethoprim, TMP = 1 0,5 2 1 MIC
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11 Ampicillin, AMP = 4 2 8 1 MIC
11 Cefotaxime, CTX <= 0.06 0,03 0,125 1 MIC
11 Chloramphenicol, CHL = 4 2 8 1 MIC
11 Ciprofloxacin, CIP = 0.016 0,004 0,016 1 MIC
11 Gentamicin, GEN = 0.5 0,25 1 1 MIC
11 Nalidixic acid, NAL = 4 1 4 1 MIC
11 Streptomycin, STR = 16 4 16 1 MIC
11 Sulfisoxazole, FIS = 16 8 32 1 MIC
11 Tetracycline, TET = 1 0,5 2 1 MIC
11 Trimethoprim, TMP = 0.5 0,5 2 1 MIC
12 Ampicillin, AMP = 2 2 8 1 MIC
12 Cefotaxime, CTX = 0.06 0,03 0,125 1 MIC
12 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
12 Chloramphenicol, CHL = 4 2 8 1 MIC
12 Ciprofloxacin, CIP = 0.03 0,004 0,016 0 MIC
12 Gentamicin, GEN = 1 0,25 1 1 MIC
12 Nalidixic acid, NAL = 2 1 4 1 MIC
12 Streptomycin, STR = 16 4 16 1 MIC
12 Tetracycline, TET <= 1 0,5 2 1 MIC
12 Trimethoprim, TMP = 1 0,5 2 1 MIC
13 Ampicillin, AMP = 4 2 8 1 MIC
13 Cefotaxime, CTX = 0.12 0,03 0,125 1 MIC
13 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
13 Chloramphenicol, CHL = 4 2 8 1 MIC
13 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
13 Gentamicin, GEN = 0.5 0,25 1 1 MIC
13 Nalidixic acid, NAL <= 4 1 4 1 MIC
13 Streptomycin, STR = 4 4 16 1 MIC
13 Sulfisoxazole, FIS = 32 8 32 1 MIC
13 Tetracycline, TET <= 1 0,5 2 1 MIC
13 Trimethoprim, TMP <= 0.5 0,5 2 1 MIC
15 Ampicillin, AMP = 24 16 22 0 DD
15 Cefotaxime, CTX = 36 29 35 0 DD
15 Cefoxitin, FOX = 27 23 29 1 DD
15 Ceftazidime, CAZ = 32 25 32 1 DD
15 Ceftiofur, XNL = 29 26 31 1 DD
15 Chloramphenicol, CHL = 26 21 27 1 DD
15 Ciprofloxacin, CIP = 35 30 40 1 DD
15 Gentamicin, GEN = 25 19 26 1 DD
15 Imipenem, IMI = 35 26 32 0 DD
15 Nalidixic acid, NAL = 24 22 28 1 DD
15 Streptomycin, STR = 20 12 20 1 DD
15 Sulfisoxazole, FIS = 16 15 23 1 DD
15 Tetracycline, TET = 24 18 25 1 DD
15 Trimethoprim, TMP = 22 21 28 1 DD
16 Ampicillin, AMP = 4 2 8 1 MIC
16 Cefotaxime, CTX = 0.06 0,03 0,125 1 MIC
16 Ceftazidime, CAZ = 0.25 0,06 0,5 1 MIC
16 Chloramphenicol, CHL = 8 2 8 1 MIC
16 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
16 Gentamicin, GEN = 0.5 0,25 1 1 MIC
16 Nalidixic acid, NAL = 2 1 4 1 MIC
16 Streptomycin, STR = 8 4 16 1 MIC
16 Sulfisoxazole, FIS = 32 8 32 1 MIC
16 Tetracycline, TET <= 1 0,5 2 1 MIC
16 Trimethoprim, TMP = 1 0,5 2 1 MIC
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17 Ampicillin, AMP = 4 2 8 1 MIC
17 Cefotaxime, CTX <= 0.06 0,03 0,125 1 MIC
17 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
17 Chloramphenicol, CHL = 4 2 8 1 MIC
17 Ciprofloxacin, CIP <= 0.008 0,004 0,016 1 MIC
17 Gentamicin, GEN = 0.5 0,25 1 1 MIC
17 Nalidixic acid, NAL <= 4 1 4 1 MIC
17 Streptomycin, STR = 4 4 16 1 MIC
17 Sulfisoxazole, FIS = 16 8 32 1 MIC
17 Tetracycline, TET <= 1 0,5 2 1 MIC
17 Trimethoprim, TMP <= 0.5 0,5 2 1 MIC
18 Ampicillin, AMP = 16 16 22 1 DD
18 Cefotaxime, CTX = 30 29 35 1 DD
18 Cefoxitin, FOX = 26 23 29 1 DD
18 Ceftiofur, XNL = 27 26 31 1 DD
18 Chloramphenicol, CHL = 26 21 27 1 DD
18 Ciprofloxacin, CIP = 35 30 40 1 DD
18 Gentamicin, GEN = 21 19 26 1 DD
18 Nalidixic acid, NAL = 26 22 28 1 DD
18 Streptomycin, STR = 16 12 20 1 DD
18 Sulfisoxazole, FIS = 23 15 23 1 DD
18 Tetracycline, TET = 24 18 25 1 DD
18 Trimethoprim, TMP = 25 21 28 1 DD
19 Ampicillin, AMP = 2 2 8 1 MIC
19 Cefotaxime, CTX = 0.06 0,03 0,125 1 MIC
19 Ceftazidime, CAZ = 0.5 0,06 0,5 1 MIC
19 Chloramphenicol, CHL = 8 2 8 1 MIC
19 Ciprofloxacin, CIP = 0.008 0,004 0,016 1 MIC
19 Gentamicin, GEN = 0.5 0,25 1 1 MIC
19 Nalidixic acid, NAL = 4 1 4 1 MIC
19 Streptomycin, STR = 16 4 16 1 MIC
19 Sulfisoxazole, FIS = 32 8 32 1 MIC
19 Tetracycline, TET = 2 0,5 2 1 MIC
19 Trimethoprim, TMP = 0.5 0,5 2 1 MIC
20 Ampicillin, AMP = 4 2 8 1 MIC
20 Cefotaxime, CTX <= 0.06 0,03 0,125 1 MIC
20 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
20 Chloramphenicol, CHL = 4 2 8 1 MIC
20 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
20 Gentamicin, GEN = 0.5 0,25 1 1 MIC
20 Nalidixic acid, NAL <= 4 1 4 1 MIC
20 Streptomycin, STR = 8 4 16 1 MIC
20 Sulfisoxazole, FIS = 16 8 32 1 MIC
20 Tetracycline, TET = 2 0,5 2 1 MIC
20 Trimethoprim, TMP <= 0.5 0,5 2 1 MIC
21 Ampicillin, AMP = 4 2 8 1 MIC
21 Cefotaxime, CTX = 0.12 0,03 0,125 1 MIC
21 Ceftazidime, CAZ = 0.5 0,06 0,5 1 MIC
21 Chloramphenicol, CHL = 8 2 8 1 MIC
21 Ciprofloxacin, CIP = 0.008 0,004 0,016 1 MIC
21 Gentamicin, GEN = 0.25 0,25 1 1 MIC
21 Nalidixic acid, NAL = 4 1 4 1 MIC
21 Sulfisoxazole, FIS = 32 8 32 1 MIC
21 Tetracycline, TET = 2 0,5 2 1 MIC
21 Trimethoprim, TMP = 0.5 0,5 2 1 MIC
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22 Ampicillin, AMP = 2 2 8 1 MIC
22 Chloramphenicol, CHL = 4 2 8 1 MIC
22 Gentamicin, GEN = 0.5 0,25 1 1 MIC
22 Sulfisoxazole, FIS = 16 8 32 1 MIC
22 Tetracycline, TET < 1 0,5 2 1 MIC
23 Ampicillin, AMP = 2 2 8 1 MIC
23 Cefotaxime, CTX = 0.06 0,03 0,125 1 MIC
23 Cefoxitin, FOX = 4 2 8 1 MIC
23 Ceftazidime, CAZ = 0.25 0,06 0,5 1 MIC
23 Chloramphenicol, CHL = 4 2 8 1 MIC
23 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
23 Gentamicin, GEN = 0.5 0,25 1 1 MIC
23 Nalidixic acid, NAL = 4 1 4 1 MIC
23 Streptomycin, STR = 4 4 16 1 MIC
23 Sulfisoxazole, FIS = 32 8 32 1 MIC
23 Tetracycline, TET = 1 0,5 2 1 MIC
23 Trimethoprim, TMP = 0.5 0,5 2 1 MIC
24 Ampicillin, AMP = 4 2 8 1 MIC
24 Cefotaxime, CTX <= 0.06 0,03 0,125 1 MIC
24 Cefoxitin, FOX <= 4 2 8 1 MIC
24 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
24 Chloramphenicol, CHL = 8 2 8 1 MIC
24 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
24 Gentamicin, GEN = 0.5 0,25 1 1 MIC
24 Imipenem, IMI <= 0.5 0,06 0,25 1 MIC
24 Nalidixic acid, NAL <= 4 1 4 1 MIC
24 Streptomycin, STR = 4 4 16 1 MIC
24 Tetracycline, TET <= 1 0,5 2 1 MIC
24 Trimethoprim, TMP <= 0.5 0,5 2 1 MIC
25 Ampicillin, AMP = 4 2 8 1 MIC
25 Cefotaxime, CTX = 0.12 0,03 0,125 1 MIC
25 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
25 Chloramphenicol, CHL = 8 2 8 1 MIC
25 Ciprofloxacin, CIP <= 0.008 0,004 0,016 1 MIC
25 Gentamicin, GEN = 0.5 0,25 1 1 MIC
25 Imipenem, IMI <= 0.5 0,06 0,25 1 MIC
25 Nalidixic acid, NAL <= 4 1 4 1 MIC
25 Streptomycin, STR = 8 4 16 1 MIC
25 Sulfisoxazole, FIS <= 8 8 32 1 MIC
25 Tetracycline, TET <= 1 0,5 2 1 MIC
25 Trimethoprim, TMP <= 0.5 0,5 2 1 MIC
26 Ampicillin, AMP = 2 2 8 1 MIC
26 Cefotaxime, CTX <= 0.06 0,03 0,125 1 MIC
26 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
26 Chloramphenicol, CHL = 4 2 8 1 MIC
26 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
26 Gentamicin, GEN = 1 0,25 1 1 MIC
26 Nalidixic acid, NAL <= 4 1 4 1 MIC
26 Streptomycin, STR = 8 4 16 1 MIC
26 Tetracycline, TET <= 1 0,5 2 1 MIC
26 Trimethoprim, TMP <= 0.5 0,5 2 1 MIC
29 Ampicillin, AMP = 2 2 8 1 MIC
29 Cefotaxime, CTX = 0.12 0,03 0,125 1 MIC
29 Ceftazidime, CAZ = 30 25 32 1 DD
29 Chloramphenicol, CHL = 4 2 8 1 MIC
29 Ciprofloxacin, CIP = 0.016 0,004 0,016 1 MIC
29 Gentamicin, GEN = 0.5 0,25 1 1 MIC
29 Nalidixic acid, NAL = 2 1 4 1 MIC
29 Streptomycin, STR = 4 4 16 1 MIC
29 Tetracycline, TET = 1 0,5 2 1 MIC
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30 Ampicillin, AMP = 4 2 8 1 MIC
30 Cefotaxime, CTX <= 0.06 0,03 0,125 1 MIC
30 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
30 Chloramphenicol, CHL = 4 2 8 1 MIC
30 Ciprofloxacin, CIP <= 0.008 0,004 0,016 1 MIC
30 Gentamicin, GEN = 0.5 0,25 1 1 MIC
30 Nalidixic acid, NAL <= 4 1 4 1 MIC
30 Streptomycin, STR = 4 4 16 1 MIC
30 Sulfisoxazole, FIS = 16 8 32 1 MIC
30 Tetracycline, TET <= 1 0,5 2 1 MIC
30 Trimethoprim, TMP <= 0.5 0,5 2 1 MIC
32 Ampicillin, AMP = 2 2 8 1 MIC
32 Cefotaxime, CTX < 0.06 0,03 0,125 1 MIC
32 Ceftazidime, CAZ < 0.25 0,06 0,5 1 MIC
32 Chloramphenicol, CHL = 4 2 8 1 MIC
32 Ciprofloxacin, CIP < 0.008 0,004 0,016 1 MIC
32 Gentamicin, GEN < 0.25 0,25 1 1 MIC
32 Nalidixic acid, NAL < 4 1 4 1 MIC
32 Streptomycin, STR = 4 4 16 1 MIC
32 Tetracycline, TET < 1 0,5 2 1 MIC
32 Trimethoprim, TMP = 1 0,5 2 1 MIC
33 Ampicillin, AMP = 4 2 8 1 MIC
33 Cefotaxime, CTX = 0.12 0,03 0,125 1 MIC
33 Cefoxitin, FOX = 4 2 8 1 MIC
33 Chloramphenicol, CHL = 4 2 8 1 MIC
33 Ciprofloxacin, CIP = 0.03 0,004 0,016 0 MIC
33 Gentamicin, GEN = 0.5 0,25 1 1 MIC
33 Nalidixic acid, NAL = 4 1 4 1 MIC
33 Streptomycin, STR = 4 4 16 1 MIC
33 Sulfisoxazole, FIS = 32 8 32 1 MIC
33 Tetracycline, TET <= 1 0,5 2 1 MIC
33 Trimethoprim, TMP = 0.5 0,5 2 1 MIC
34 Ampicillin, AMP = 8 2 8 1 MIC
34 Cefotaxime, CTX = 0.12 0,03 0,125 1 MIC
34 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
34 Chloramphenicol, CHL = 8 2 8 1 MIC
34 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
34 Gentamicin, GEN = 0.5 0,25 1 1 MIC
34 Nalidixic acid, NAL <= 4 1 4 1 MIC
34 Streptomycin, STR <= 2 4 16 0 MIC
34 Sulfisoxazole, FIS = 32 8 32 1 MIC
34 Tetracycline, TET = 2 0,5 2 1 MIC
34 Trimethoprim, TMP = 2 0,5 2 1 MIC
37 Ampicillin, AMP = 4 2 8 1 AGA
37 Cefotaxime, CTX <= 0.06 0,03 0,125 1 AGA
37 Chloramphenicol, CHL = 4 2 8 1 AGA
37 Ciprofloxacin, CIP <= 0.008 0,004 0,016 1 AGA
37 Gentamicin, GEN = 0.5 0,25 1 1 AGA
37 Nalidixic acid, NAL <= 2 1 4 1 AGA
37 Streptomycin, STR = 8 4 16 1 AGA
37 Tetracycline, TET = 1 0,5 2 1 AGA
37 Trimethoprim, TMP = 0.5 0,5 2 1 AGA
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38 Ampicillin, AMP = 16 16 22 1 DD
38 Cefotaxime, CTX = 34.3 29 35 1 DD
38 Cefoxitin, FOX = 27.9 23 29 1 DD
38 Chloramphenicol, CHL = 26.2 21 27 1 DD
38 Ciprofloxacin, CIP = 37.1 30 40 1 DD
38 Gentamicin, GEN = 23.6 19 26 1 DD
38 Imipenem, IMI = 29.7 26 32 1 DD
38 Nalidixic acid, NAL = 23 22 28 1 DD
38 Streptomycin, STR = 15.1 12 20 1 DD
38 Tetracycline, TET = 24.2 18 25 1 DD
38 Trimethoprim, TMP = 24 21 28 1 DD
39 Ampicillin, AMP = 4 2 8 1 MIC
39 Cefotaxime, CTX = 0.12 0,03 0,125 1 MIC
39 Ceftiofur, XNL = 0.5 0,25 1 1 MIC
39 Chloramphenicol, CHL = 4 2 8 1 MIC
39 Ciprofloxacin, CIP = 0.016 0,004 0,016 1 MIC
39 Gentamicin, GEN = 1 0,25 1 1 MIC
39 Nalidixic acid, NAL < 2 1 4 1 MIC
39 Streptomycin, STR = 8 4 16 1 MIC
39 Tetracycline, TET = 1 0,5 2 1 MIC
39 Trimethoprim, TMP = 1 0,5 2 1 MIC
40 Ampicillin, AMP = 20 16 22 1 DD
40 Cefotaxime, CTX = 29 29 35 1 DD
40 Cefoxitin, FOX = 24 23 29 1 DD
40 Ceftazidime, CAZ = 26 25 32 1 DD
40 Ceftiofur, XNL = 24 26 31 0 DD
40 Chloramphenicol, CHL = 24 21 27 1 DD
40 Ciprofloxacin, CIP = 36 30 40 1 DD
40 Gentamicin, GEN = 21 19 26 1 DD
40 Imipenem, IMI = 30 26 32 1 DD
40 Nalidixic acid, NAL = 24 22 28 1 DD
40 Streptomycin, STR = 16 12 20 1 DD
40 Sulfisoxazole, FIS = 20 15 23 1 DD
40 Tetracycline, TET = 22 18 25 1 DD
40 Trimethoprim, TMP = 27 21 28 1 DD
41 Ampicillin, AMP = 8 2 8 1 MIC
41 Cefotaxime, CTX = 0.12 0,03 0,125 1 MIC
41 Ceftazidime, CAZ <= 0.25 0,06 0,5 1 MIC
41 Chloramphenicol, CHL = 8 2 8 1 MIC
41 Ciprofloxacin, CIP = 0.015 0,004 0,016 1 MIC
41 Gentamicin, GEN = 0.5 0,25 1 1 MIC
41 Nalidixic acid, NAL <= 4 1 4 1 MIC
41 Streptomycin, STR = 8 4 16 1 MIC
41 Tetracycline, TET = 2 0,5 2 1 MIC
41 Trimethoprim, TMP <= 0.5 0,5 2 1 MIC
44 Ampicillin, AMP <= 8 2 8 1 AGA
44 Cefotaxime, CTX <= 1 0,03 0,125 1 AGA
44 Chloramphenicol, CHL <= 8 2 8 1 AGA
44 Ciprofloxacin, CIP <= 0.125 0,004 0,016 1 AGA
44 Gentamicin, GEN <= 4 0,25 1 1 AGA
44 Nalidixic acid, NAL <= 16 1 4 1 AGA
44 Streptomycin, STR <= 16 4 16 1 AGA
44 Sulfisoxazole, FIS <= 64 8 32 1 AGA
44 Tetracycline, TET <= 8 0,5 2 1 AGA
44 Trimethoprim, TMP <= 2 0,5 2 1 AGA
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Test results from the reference strain C. jejuni ATCC 33560
Lab no. Antimicrobial Operator Value Low limit High limit Mark Method 36-37ºC/48h 42ºC/24h
1 Chloramphenicol, CHL = 8 1 8 1 MIC X
1 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
1 Erythromycin, ERY = 2 0,5 2 1 MIC X
1 Gentamicin, GEN = 0.5 0,5 2 1 MIC X
1 Nalidixic acid, NAL = 8 4 16 1 MIC X
1 Tetracycline, TET = 2 0,25 2 1 MIC X
2 Chloramphenicol, CHL = 8 1 8 1 MIC X
2 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
2 Erythromycin, ERY = 2 0,5 2 1 MIC X
2 Gentamicin, GEN = 0.25 0,5 2 0 MIC X
2 Nalidixic acid, NAL = 8 4 16 1 MIC X
2 Tetracycline, TET = 2 0,25 2 1 MIC X
4 Chloramphenicol, CHL = 4 1 8 1 MIC X
4 Ciprofloxacin, CIP = 0.12 0,06 0,25 1 MIC X
4 Erythromycin, ERY = 0.5 0,5 2 1 MIC X
4 Gentamicin, GEN = 1 0,5 2 1 MIC X
4 Nalidixic acid, NAL = 8 4 16 1 MIC X
4 Tetracycline, TET = 0.5 0,25 2 1 MIC X
6 Chloramphenicol, CHL = 4 1 4 1 MIC X
6 Ciprofloxacin, CIP = 1 0,03 0,125 0 MIC X
6 Erythromycin, ERY = 4 0,25 2 0 MIC X
6 Nalidixic acid, NAL = 8 4 16 1 MIC X
6 Tetracycline, TET = 2 0,25 1 0 MIC X
9 Chloramphenicol, CHL = 4 1 8 1 MIC X
9 Ciprofloxacin, CIP = 0.12 0,06 0,25 1 MIC X
9 Erythromycin, ERY = 1 0,5 2 1 MIC X
9 Gentamicin, GEN = 1 0,5 2 1 MIC X
9 Nalidixic acid, NAL = 8 4 16 1 MIC X
9 Tetracycline, TET = 0.5 0,25 2 1 MIC X
11 Ciprofloxacin, CIP = 0.12 0,06 0,25 1 MIC X
11 Erythromycin, ERY = 1 0,5 2 1 MIC X
11 Gentamicin, GEN = 1 0,5 2 1 MIC X
11 Nalidixic acid, NAL = 8 4 16 1 MIC X
11 Tetracycline, TET = 1 0,25 2 1 MIC X
12 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
12 Erythromycin, ERY = 1 0,5 2 1 MIC X
12 Gentamicin, GEN = 1 0,5 2 1 MIC X
12 Nalidixic acid, NAL = 8 4 16 1 MIC X
12 Tetracycline, TET = 1 0,25 2 1 MIC X
14 Chloramphenicol, CHL <= 2 1 4 1 MIC X
14 Ciprofloxacin, CIP = 0.125 0,03 0,125 1 MIC X
14 Erythromycin, ERY <= 0.5 0,25 2 1 MIC X
14 Gentamicin, GEN = 1 0,25 2 1 MIC X
14 Nalidixic acid, NAL = 4 4 16 1 MIC X
14 Tetracycline, TET = 0.5 0,25 1 1 MIC X
15 Ciprofloxacin, CIP = 0.064 0,06 0,5 1 AGA X
15 Erythromycin, ERY = 0.5 1 4 0 AGA X
15 Gentamicin, GEN = 0.38 0,5 4 0 AGA X
15 Nalidixic acid, NAL = 3 0 256 0 AGA X
15 Tetracycline, TET = 0.38 0 256 0 AGA X
17 Chloramphenicol, CHL = 4 1 8 1 MIC X
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17 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
17 Erythromycin, ERY = 1 0,5 2 1 MIC X
17 Gentamicin, GEN = 1 0,5 2 1 MIC X
17 Nalidixic acid, NAL = 8 4 16 1 MIC X
17 Tetracycline, TET = 0.5 0,25 2 1 MIC X
19 Chloramphenicol, CHL = 4 1 4 1 MIC X
19 Ciprofloxacin, CIP = 0.12 0,03 0,125 1 MIC X
19 Erythromycin, ERY = 0.5 0,25 2 1 MIC X
19 Gentamicin, GEN = 1 0,25 2 1 MIC X
19 Nalidixic acid, NAL = 8 4 16 1 MIC X
19 Tetracycline, TET = 2 0,25 1 0 MIC X
20 Chloramphenicol, CHL <= 2 1 8 1 MIC X
20 Ciprofloxacin, CIP = 0.12 0,06 0,25 1 MIC X
20 Erythromycin, ERY <= 0.5 0,5 2 1 MIC X
20 Gentamicin, GEN = 0.5 0,5 2 1 MIC X
20 Nalidixic acid, NAL = 8 4 16 1 MIC X
20 Tetracycline, TET = 1 0,25 2 1 MIC X
22 Ciprofloxacin, CIP = 0.12 0,06 0,25 1 MIC X
22 Erythromycin, ERY = 1 0,5 2 1 MIC X
22 Nalidixic acid, NAL = 8 4 16 1 MIC X
22 Tetracycline, TET = 1 0,25 2 1 MIC X
24 Chloramphenicol, CHL = 4 1 8 1 MIC X
24 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
24 Erythromycin, ERY = 2 0,5 2 1 MIC X
24 Gentamicin, GEN <= 0.25 0,5 2 0 MIC X
24 Nalidixic acid, NAL = 8 4 16 1 MIC X
24 Tetracycline, TET = 2 0,25 2 1 MIC X
25 Chloramphenicol, CHL = 8 1 8 1 MIC X
25 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
25 Erythromycin, ERY = 2 0,5 2 1 MIC X
25 Gentamicin, GEN <= 0.25 0,5 2 0 MIC X
25 Nalidixic acid, NAL = 8 4 16 1 MIC X
25 Tetracycline, TET = 2 0,25 2 1 MIC X
26 Chloramphenicol, CHL <= 2 1 8 1 MIC X
26 Ciprofloxacin, CIP = 0.12 0,06 0,25 1 MIC X
26 Erythromycin, ERY <= 0.5 0,5 2 1 MIC X
26 Gentamicin, GEN = 1 0,5 2 1 MIC X
26 Nalidixic acid, NAL = 8 4 16 1 MIC X
26 Tetracycline, TET = 1 0,25 2 1 MIC X
29 Ciprofloxacin, CIP = 0.12 0,06 0,25 1 MIC X
29 Erythromycin, ERY = 0.5 0,5 2 1 MIC X
29 Gentamicin, GEN = 1 0,5 2 1 MIC X
29 Nalidixic acid, NAL = 16 4 16 1 MIC X
29 Tetracycline, TET = 2 0,25 2 1 MIC X
30 Chloramphenicol, CHL <= 2 1 8 1 MIC X
30 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
30 Erythromycin, ERY <= 0.5 0,5 2 1 MIC X
30 Gentamicin, GEN = 1 0,5 2 1 MIC X
30 Nalidixic acid, NAL = 8 4 16 1 MIC X
30 Tetracycline, TET = 1 0,25 2 1 MIC X
32 Chloramphenicol, CHL = 4 1 8 1 MIC X
32 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
32 Erythromycin, ERY = 2 0,5 2 1 MIC X
32 Gentamicin, GEN = 2 0,5 2 1 MIC X
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32 Nalidixic acid, NAL = 16 4 16 1 MIC X
32 Tetracycline, TET = 1 0,25 2 1 MIC X
33 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
33 Erythromycin, ERY = 2 0,5 2 1 MIC X
33 Gentamicin, GEN = 1 0,5 2 1 MIC X
33 Nalidixic acid, NAL = 16 4 16 1 MIC X
33 Tetracycline, TET = 1 0,25 2 1 MIC X
34 Chloramphenicol, CHL = 4 1 8 1 MIC X
34 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
34 Erythromycin, ERY = 2 0,5 2 1 MIC X
34 Gentamicin, GEN = 0.5 0,5 2 1 MIC X
34 Nalidixic acid, NAL = 8 4 16 1 MIC X
34 Tetracycline, TET = 2 0,25 2 1 MIC X
37 Chloramphenicol, CHL = 4 0 256 0 AGA X
37 Ciprofloxacin, CIP = 0.25 0,12 1 1 AGA X
37 Erythromycin, ERY = 1 1 8 1 AGA X
37 Gentamicin, GEN = 1 0,5 2 1 AGA X
37 Nalidixic acid, NAL = 8 0 256 0 AGA X
37 Tetracycline, TET = 1 0 256 0 AGA X
39 Ciprofloxacin, CIP = 0.12 0,06 0,25 1 MIC X
39 Erythromycin, ERY = 0.5 0,5 2 1 MIC X
39 Nalidixic acid, NAL = 16 4 16 1 MIC X
39 Tetracycline, TET = 1 0,25 2 1 MIC X
41 Chloramphenicol, CHL <= 2 1 4 1 MIC X
41 Ciprofloxacin, CIP <= 0.06 0,03 0,125 1 MIC X
41 Erythromycin, ERY <= 0.5 0,25 2 1 MIC X
41 Gentamicin, GEN = 0.5 0,25 2 1 MIC X
41 Nalidixic acid, NAL = 4 4 16 1 MIC X
41 Tetracycline, TET = 0.5 0,25 1 1 MIC X
44 Chloramphenicol, CHL = 4 0 256 0 AGA X
44 Ciprofloxacin, CIP = 1 0,12 1 1 AGA X
44 Erythromycin, ERY = 4 1 8 1 AGA X
44 Gentamicin, GEN = 0.5 0,5 2 1 AGA X
44 Nalidixic acid, NAL = 8 0 256 0 AGA X
44 Tetracycline, TET = 8 0 256 0 AGA X
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QC ranges for reference strains
Antimicrobial MIC E-test
Ampicillin, AMP 2-8 2-8
Cefotaxime, CTX 0.03-0.12 0.03-0.12
Cefoxitin, FOX 2-8 None
Ceftazidime, CAZ 0.06-0.5 0.06-0.5
Ceftiofur, XNL 0.25-1 None
Chloramphenicol, CHL 2-8 None
Ciprofloxacin, CIP 0.004-0.016 None
Gentamicin, GEN 0.25-1 None
Imipenem, IMI 0.06-0.25 0.06-0.25
Nalidixic acid, NAL 1-4 1-4
Streptomycin, STR 4-16 2-8
Sulfisoxazole, FIS 8-32 32-128
Tetracycline, TET 0.5-2 0.5-2
Trimethoprim, TMP 0.5-2 0.5-2
E-test ranges are according to AB-Biodisk
Antimicrobial Microbroth                
(36-37°C/48h)
Microbroth 
(42°C/24h)
Agar dilution     
(36-37°C/48h)
Agar dilution     
(42°C/24h)
Chloramphenicol, CHL 1-8 1-4 None None
Ciprofloxacin, CIP 0.06-0.25 0.03-0.12 0.12-1 0.06-0.5
Erythromycin, ERY 0.5-2 0.25-2 1-8 1-4
Gentamicin, GEN 0.5-2 0.25-2 0.5-2 0.5-4
Nalidixic acid, NAL 4-16 4-16 None None
Tetracycline, TET 0.25-2 0.25-1 None None
Ranges are according to CLSI (M31-A3) 
Campylobacter jejuni ATCC 33560
E. coli ATCC 25922
DD (disc content)
16-22 (10µg)
29-35 (30µg)
23-29 (30µg)
25-32 (30µg)
26-31 (30µg)
21-27 (30µg)
21-28 (5µg)
MIC ranges and disc diffusion ranges are according to CLSI M100 S20 with the following exceptions: 
The MIC range for streptomycin is according to Sensititre and the range for ceftiofur is according to 
M31-A3. Additionally, the range for ciprofloxacin is extended to include 0.016 as well.
22-28 (30µg)
12-20 (10µg)
15-23 (250/300µg)
30-40 (5µg)
19-26 (10µg)
26-32 (10µg)
18-25 (30µg)
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Test range for MIC (µg/mL) - Salmonella
Lab no Method Test range for 
MIC (ug/mL)
Lab no Method Test range for 
MIC (ug/mL)
Lab no Method Test range for 
MIC (ug/mL)
Lab no Method Test range for 
MIC (ug/mL)
1 MIC 1-32 1 MIC 2-64 1 MIC 4-64 1 MIC 2-32
2 MIC 0.5-32 2 MIC 2-64 2 MIC 4-64 2 MIC 1-64
4 MIC 0.5-32 4 MIC 2-64 4 MIC 4-64 4 MIC 1-64
6 MIC 0.5-32 6 MIC 2-64 6 MIC 4-64 6 MIC 1-64
9 MIC 0.5-32 9 MIC 2-64 9 MIC 4-64 9 MIC 1-64
11 MIC 0.5-64 11 MIC 2-256 11 MIC 2-256 11 MIC 0.5-64
12 MIC 1-128 12 MIC 2-64 12 MIC 1-128 12 MIC 1-128
13 MIC 0.5-32 13 MIC 2-64 13 MIC 8-64 13 MIC 1-64
16 MIC 1-128 16 MIC 2-256 16 MIC 1-128 16 MIC 1-128
17 MIC 0.5-32 17 MIC 2-64 17 MIC 4-64 17 MIC 1-64
20 MIC 0.5-32 20 MIC 2-64 20 MIC 4-64 20 MIC 1-64
22 MIC 0.5-32 22 MIC 2-64 22 MIC 4-64 22 MIC 1-64
23 MIC 0.5-32 23 MIC 2-64 23 MIC 4-64 23 MIC 1-64
24 MIC 0.5-32 24 MIC 2-64 24 MIC 4-64 24 MIC 1-64
25 MIC 0.5-32 25 MIC 2-64 25 MIC 4-64 25 MIC 1-64
26 MIC 0.5-32 26 MIC 2-64 26 MIC 4-64 26 MIC 1-64
29 MIC >4 29 MIC >16 29 MIC >16 29 MIC >8
30 MIC 0.5-32 30 MIC 2-64 30 MIC 4-64 30 MIC 1-64
32 MIC 0,5-32 32 MIC 2-64 32 MIC 4-64 32 MIC 1-64
33 MIC 0.5-64 33 MIC 2-256 33 MIC 2-256 33 MIC 0.5-64
37 AGA 0.5-64 37 AGA 2-256 37 AGA 2-512 37 AGA 0.5 - 64
39 MIC 0.5-64 39 MIC 2-256 39 MIC 2-256 39 MIC 0.5-64
41 MIC 0.5-32 41 MIC 2 - 64 41 MIC 4 - 64
44 AGA 8 and 128 44 AGA 8 44 AGA 16 41 MIC 1 - 64
44 AGA 8 and 128
1 MIC 0.125-4 1 MIC 0.015-4 1 MIC 8-128 1 MIC 1-32
2 MIC 0.06 - 4 2 MIC 0.008-8 2 MIC 2-128 2 MIC 0.5-32
4 MIC 0.06 - 4 4 MIC 0.008-8 4 MIC 2-128 4 MIC 0.5-32
6 MIC 0.06-4 6 MIC 0.008-8 6 MIC 2-128 6 MIC 0.5-32
9 MIC 0.06-4 9 MIC 0.008-8 9 MIC 2-128 9 MIC 0.5-32
11 MIC 0.06-8 11 MIC 0.008-1 11 MIC 2-256 11 MIC 0.25-32
12 MIC 0.016-2 12 MIC 0.008-1 12 MIC 2-256 12 MIC 0.12-16
13 MIC 0.06-4 13 MIC 0.008-8 13 MIC 2-128 13 MIC 0.5-32
16 MIC 0.015-2 16 MIC 0.008-4 16 MIC 2-256 16 MIC 0.12-16
17 MIC 0.06-4 17 MIC 0.008-8 17 MIC 2-128 17 MIC 0.5-32
20 MIC 0.06-4 20 MIC 0.008-8 20 MIC 2-128 20 MIC 0.5-32
22 MIC 0.06-4 22 MIC 0.008-8 22 MIC 2-128 22 MIC 0.5-32
23 MIC 0.06-4 23 MIC 0.008-8 23 MIC 2-128 23 MIC 0.5-32
24 MIC 0.06-4 24 MIC 0.008-8 24 MIC 2-128 24 MIC 0.5-32
25 MIC 0.06-4 25 MIC 0.008-8 25 MIC 2-128 25 MIC 0.5-32
26 MIC 0.06-4 26 MIC 0.008-8 26 MIC 2-128 26 MIC 0.5-32
29 MIC >0.5 29 MIC >0.06 29 MIC >32 29 MIC >2
30 MIC 0.06-4 30 MIC 0.008-8 30 MIC 2-128 30 MIC 0.5-32
32 MIC 0,06-4 32 MIC 0.008-8 32 MIC 2-128 32 MIC 0,5-32
33 MIC 0.06-8 33 MIC 0.008-8 33 MIC 2-256 33 MIC 0.25-32
37 AGA 0.06-8 37 AGA 0.008-8 37 AGA 2-512 37 AGA 0.25-32
39 MIC 0.06-8 39 MIC 0.008-1 39 MIC 2-256 39 MIC 0.25-32
41 MIC 0.06-4 41 MIC 0.008-8 41 MIC 2 - 128 41 MIC 0.5-32
44 AGA 1 44 AGA 0.125 and 1 44 AGA 16 and 128 44 AGA 2
2 MIC 0.25 - 16 1 MIC 0.5-16 1 MIC 64-1024      Antimicrobials recommended 
4 MIC 0.25 - 16 2 MIC 0.25-32 2 MIC 8-1024      by EFSA are marked in grey
6 MIC 0.25-16 4 MIC 0.25-32 4 MIC 8-1024
9 MIC 0.25-16 6 MIC 0.25-32 6 MIC 8-1024      Participants' ranges covering 
12 MIC 0.25-16 9 MIC 0.25-32 9 MIC 8-1024      the EFSA range are 
13 MIC 0.25-16 11 MIC 0.25-32 11 MIC 8-1024      marked in grey
16 MIC 0.06-8 12 MIC 0.12-16 12 MIC 16-2048
17 MIC 0.25-16 13 MIC 0.25-32 13 MIC 8-1024      MIC: Microbroth dilution
20 MIC 0.25-16 16 MIC 0.12-16 16 MIC 8-1024      AGA: Agar dilution
22 MIC 0.25-16 17 MIC 0.25-32 17 MIC 8-1024
23 MIC 0.25-16 20 MIC 0.25-32 20 MIC 8-1024
24 MIC 0.25-16 22 MIC 0.25-32 22 MIC 8-1024
25 MIC 0.25 - 16 23 MIC 0.25-32 23 MIC 8-1024
26 MIC 0.25-16 24 MIC 0.25-32 24 MIC 8-1024
29 MIC >2 25 MIC 0.25-32 25 MIC 8-1024
30 MIC 0.25-16 26 MIC 0.25-32 26 MIC 8-1024
32 MIC 0,25-16 29 MIC >2 29 MIC >256
39 MIC N/A 30 MIC 0.25-32 30 MIC 8-1024
41 MIC 0.25 - 16 32 MIC 0.25-32 32 MIC 8-1024
33 MIC 0.25-32 33 MIC 8-1024
1 MIC 0.5-8 37 AGA 0.25-32 37 AGA 8-1024
12 MIC 0.12-16 39 MIC 0.25-32 39 MIC 8-1024
23 MIC 0,12-8 41 MIC 0.25-32 41 MIC 8-1024
29 MIC >2 44 AGA 4 44 AGA 64
39 MIC N/A
Ceftiofur, XNL
Nalidixic acid, NAL
Gentamicin, GEN
Ciprofloxacin, CIP
Chloramphenicol, CHL
Streptomycin, STR
Trimethoprim, TMP
Tetracycline, TET
Sulfamethoxazole, SMX
Ampicillin, AMP
Cefotaxime, CTX
Ceftazidime, CAZ
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Test range for MIC (µg/mL) - Campylobacter
Lab no Method Test range for 
MIC (ug/mL)
Lab no Method Test range for 
MIC (ug/mL)
Lab no Method Test range for 
MIC (ug/mL)
1 MIC 2-32 1 MIC 0.125-16 1 MIC 1-16
2 MIC 2 - 64 2 MIC 0.12-16 2 MIC 0.5-32
4 MIC 2 - 32 4 MIC 0.12-16 4 MIC 1-16
6 MIC 2-32 6 MIC 0.12-16 6 MIC 1-16
9 MIC 2-32 9 MIC 0.12-16 9 MIC 1-16
14 MIC 2-32 11 MIC 0.12-16 11 MIC 0.5-64
17 MIC 2-32 12 MIC 0.12-16 12 MIC 0.5-64
19 MIC 2-32 14 MIC 0.125-16 14 MIC 1-16
20 MIC 2-32 15 AGA 0.016-256 17 MIC 1-16
21 MIC 1-32 17 MIC 0.12-16 19 MIC 1-16
22 MIC 2-32 19 MIC 0.12-16 20 MIC 1-16
23 MIC 2-32 20 MIC 0.12-16 21 MIC 0.12-128
24 MIC 2-128 21 MIC 0.12-128 22 MIC 1-16
25 MIC 2 - 128 22 MIC 0.12-16 23 MIC 1-16
26 MIC 2-32 23 MIC 0.12-16 24 MIC 1-128
30 MIC 2-32 24 MIC 0.25-32 25 MIC 1-128
32 MIC 2-32 25 MIC 0.25-32 26 MIC 1-16
34 MIC 1 to 32 26 MIC 0.12-16 29 MIC 0.5-64
37 AGA 2 - 256 29 MIC 0.12-16 30 MIC 1-16
39 MIC N/A 30 MIC 0.12-16 32 MIC 1-16
41 MIC 2 - 32 32 MIC 0.125-16 33 MIC 0.5-64
44 AGA 8 33 MIC 0.12-16 34 MIC 0.25 to 64
34 MIC 0.125 to 32 37 AGA 0.5-32
1 MIC 0.06-4 37 AGA 0.125-16 39 MIC 0.5-64
2 MIC 0.06-32 39 MIC 0.12-16 41 MIC 1 - 16
4 MIC 0.06-4 41 MIC 0.12-16 44 AGA not tested
6 MIC 0.06-4 44 AGA 4
9 MIC 0,06-4 1 MIC 0.25-16
11 MIC 0.06-8 1 MIC 2-64 2 MIC 0.12-64
12 MIC 0.06-8 2 MIC 2 - 256 4 MIC 0.25-16
14 MIC 0.06-4 4 MIC 2 - 64 6 MIC 0.25-16
15 AGA 0.002-32 6 MIC 2-64 9 MIC 0,25-16
17 MIC 0.06-4 9 MIC 2-64 11 MIC 0.12-16
19 MIC 0.06-4 11 MIC 1-64 12 MIC 0.12-16
20 MIC 0.06-4 12 MIC 1-64 14 MIC 0.25-16
21 MIC 0.06-128 14 MIC 2-64 15 AGA 0.016-256
22 MIC 0.06-4 15 AGA 0.016-256 17 MIC 0.25-16
23 MIC 0.06-4 17 MIC 2-64 19 MIC 0.25-16
24 MIC 0.12-16 19 MIC 2-64 20 MIC 0.25-16
25 MIC 0.12-16 20 MIC 2-64 21 MIC 0.12-128
26 MIC 0.06-4 21 MIC 0.12-128 22 MIC 0.25-16
29 MIC 0.06-8 22 MIC 2-64 23 MIC 0.25-16
30 MIC 0.06-4 23 MIC 2-64 24 MIC 0.5-64
32 MIC 0.06-4 24 MIC 1-128 25 MIC 0.5-64
33 MIC 0.06-8 25 MIC 1 - 128 26 MIC 0.25-16
34 MIC 0.032 to 32 26 MIC 2-64 29 MIC 0.12-16
37 AGA 0.06-8 29 MIC 1-64 30 MIC 0.25-16
39 MIC 0.06-8 30 MIC 2-64 32 MIC 0.25-16
41 MIC 0.06-4 32 MIC 2-64 33 MIC 0.12-16
44 AGA 1 33 MIC 1-64 34 MIC 0.125 to 256
34 MIC 0.5 to 64 37 AGA 0.125 - 16
1 MIC 0.5-32 37 AGA 2 - 256 39 MIC 0.12-16
2 MIC 0.25-128 39 MIC 1-64 41 MIC 0.25 - 16
4 MIC 0.5-32 41 MIC 2 - 64 44 AGA 8 & 128
6 MIC 0.5-32 44 AGA 16
9 MIC 0,5-32
11 MIC 0.5-64
12 MIC 0.5-64
14 MIC 0.5-32
15 AGA 0.016-256      Antimicrobials recommended by EFSA are marked in grey
17 MIC 0.5-32      Participants' ranges covering the EFSA range are marked in grey
19 MIC 0.5-32
20 MIC 0.5-32      MIC: Microbroth dilution
21 MIC 0.12-128      AGA: Agar dilution
22 MIC 0.5-32
23 MIC 0.5-32
24 MIC 0.5-64
25 MIC 0.5-64
26 MIC 0.5-32
29 MIC 0.5-64
30 MIC 0.5-32
32 MIC 0.5-32
33 MIC 0.5-64
34 MIC 0.125 to 128
37 AGA 0.5-64
39 MIC 0.5-64
41 MIC 0.5-32
44 AGA 4
Erythromycin, ERY
Nalidixic acid, NAL
Ciprofloxacin, CIP
Tetracycline,TET
Gentamicin, GEN Streptomycin, STRChloramphenicol, CHL
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Salmonella - expected and obtained interpretation
Antimicrobial Strain Expected % R % S No. 
correct
No. 
incorrect
EURL S-5.1 R 100 0 31 0
EURL S-5.2 R 100 0 31 0
EURL S-5.3 S 3 97 30 1
EURL S-5.4 S 0 100 31 0
EURL S-5.5 R 100 0 31 0
EURL S-5.6 R 100 0 31 0
EURL S-5.7 R 100 0 31 0
EURL S-5.8 R 100 0 31 0
EURL S-5.1 S 0 100 31 0
EURL S-5.2 S 0 100 31 0
EURL S-5.3 S 0 100 31 0
EURL S-5.4 S 0 100 31 0
EURL S-5.5 S 3 97 30 1
EURL S-5.6 S 0 100 31 0
EURL S-5.7 R 100 0 31 0
EURL S-5.8 R 100 0 31 0
EURL S-5.1 S 0 100 24 0
EURL S-5.2 S 0 100 24 0
EURL S-5.3 S 0 100 24 0
EURL S-5.4 S 0 100 25 0
EURL S-5.5 S 0 100 24 0
EURL S-5.6 S 0 100 24 0
EURL S-5.7 S 17 83 19 4
EURL S-5.8 R 100 0 25 0
EURL S-5.1 S 0 100 7 0
EURL S-5.2 S 0 100 7 0
EURL S-5.3 S 0 100 7 0
EURL S-5.4 S 0 100 7 0
EURL S-5.5 S 0 100 7 0
EURL S-5.6 S 0 100 7 0
EURL S-5.7 R 100 0 7 0
EURL S-5.8 R 100 0 7 0
EURL S-5.1 R 100 0 31 0
EURL S-5.2 S 6 94 29 2
EURL S-5.3 R 100 0 31 0
EURL S-5.4 S 0 100 30 0
EURL S-5.5 S 0 100 31 0
EURL S-5.6 S 0 100 31 0
EURL S-5.7 S 0 100 31 0
EURL S-5.8 S 0 100 31 0
EURL S-5.1 R 94 6 29 2
EURL S-5.2 R 90 10 28 3
EURL S-5.3 R 90 10 28 3
EURL S-5.4 S 0 100 31 0
EURL S-5.5 R 84 16 26 5
EURL S-5.6 R 84 16 26 5
EURL S-5.7 R 87 13 27 4
EURL S-5.8 S 0 100 31 0
Ampicillin, AMP
Ciprofloxacin, CIP
Chloramphenicol, CHL
Ceftiofur, XNL
Ceftazidime, CAZ
Cefotaxime, CTX
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EURL S-5.1 S 0 100 31 0
EURL S-5.2 S 0 100 31 0
EURL S-5.3 R 90 10 27 3
EURL S-5.4 S 0 100 31 0
EURL S-5.5 S 0 100 31 0
EURL S-5.6 S 0 100 31 0
EURL S-5.7 S 0 100 31 0
EURL S-5.8 S 0 100 31 0
EURL S-5.1 R 100 0 31 0
EURL S-5.2 R 97 3 30 1
EURL S-5.3 R 100 0 31 0
EURL S-5.4 S 3 97 30 1
EURL S-5.5 S 16 84 26 5
EURL S-5.6 S 3 97 30 1
EURL S-5.7 R 97 3 30 1
EURL S-5.8 S 3 97 30 1
EURL S-5.1 R 94 6 29 2
EURL S-5.2* R 48* 52 15 16
EURL S-5.3* R 26* 74 8 23
EURL S-5.4 S 0 100 31 0
EURL S-5.5 R 100 0 31 0
EURL S-5.6 S 0 100 31 0
EURL S-5.7 S 6 94 29 2
EURL S-5.8 S 6 94 29 2
EURL S-5.1 R 100 0 31 0
EURL S-5.2 R 100 0 31 0
EURL S-5.3 R 100 0 31 0
EURL S-5.4 S 3 97 30 1
EURL S-5.5 S 0 100 31 0
EURL S-5.6 S 6 94 29 2
EURL S-5.7 S 3 97 30 1
EURL S-5.8 S 0 100 31 0
EURL S-5.1 R 100 0 31 0
EURL S-5.2 S 6 94 29 2
EURL S-5.3 R 100 0 31 0
EURL S-5.4 S 0 100 31 0
EURL S-5.5 S 3 97 30 1
EURL S-5.6 S 0 100 31 0
EURL S-5.7 R 97 3 30 1
EURL S-5.8 S 0 100 31 0
EURL S-5.1 R 100 0 31 0
EURL S-5.2 R 100 0 31 0
EURL S-5.3 R 100 0 31 0
EURL S-5.4 S 0 100 31 0
EURL S-5.5 S 0 100 31 0
EURL S-5.6 S 0 100 31 0
EURL S-5.7 S 0 100 31 0
EURL S-5.8 S 0 100 31 0
*Strain/antimicrobial-combination excluded from the evaluation
Gentamicin, GEN
Nalidixic acid, NAL
Trimethoprim, TMP
Tetracycline, TET
Sulphonamides, SMX
Streptomycin, STR
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Campylobacter  - expected and obtained interpretation
 
Antimicrobial Strain Expected % R % S No. correct
No. 
incorrect
EURL C-5.1 S 0 100 21 0
EURL C-5.2 S 0 100 21 0
EURL C-5.3 S 0 100 21 0
EURL C-5.4 S 0 100 21 0
EURL C-5.5 S 0 100 21 0
EURL C-5.6 S 0 100 21 0
EURL C-5.7 S 0 100 20 0
EURL C-5.8 S 0 100 20 0
EURL C-5.1 S 0 100 27 0
EURL C-5.2 R 100 0 27 0
EURL C-5.3 S 0 100 27 0
EURL C-5.4 S 0 100 27 0
EURL C-5.5 R 96 4 26 1
EURL C-5.6 S 0 100 27 0
EURL C-5.7 S 4 96 25 1
EURL C-5.8 R 100 0 26 0
EURL C-5.1 S 0 100 27 0
EURL C-5.2 R 100 0 27 0
EURL C-5.3 R 100 0 27 0
EURL C-5.4 R 100 0 27 0
EURL C-5.5 S 4 96 26 1
EURL C-5.6 R 100 0 27 0
EURL C-5.7 S 4 96 25 1
EURL C-5.8 S 0 100 26 0
EURL C-5.1 S 0 100 27 0
EURL C-5.2 S 0 100 27 0
EURL C-5.3 S 0 100 27 0
EURL C-5.4 S 0 100 27 0
EURL C-5.5 S 0 100 27 0
EURL C-5.6 S 0 100 27 0
EURL C-5.7 S 0 100 26 0
EURL C-5.8 S 0 100 26 0
EURL C-5.1 S 0 100 27 0
EURL C-5.2 R 93 7 25 2
EURL C-5.3 S 0 100 27 0
EURL C-5.4 S 4 96 26 1
EURL C-5.5 R 96 4 26 1
EURL C-5.6 S 0 100 27 0
EURL C-5.7 S 4 96 25 1
EURL C-5.8 R 100 0 26 0
EURL C-5.1 S 0 100 26 0
EURL C-5.2 R 100 0 26 0
EURL C-5.3 S 4 96 24 1
EURL C-5.4 S 12 88 23 3
EURL C-5.5 R 92 8 24 2
EURL C-5.6 S 12 88 23 3
EURL C-5.7 S 0 100 24 0
EURL C-5.8 S 0 100 24 0
EURL C-5.1 S 0 100 27 0
EURL C-5.2 R 89 11 24 3
EURL C-5.3 S 15 85 23 4
EURL C-5.4 S 15 85 22 4
EURL C-5.5 S 0 100 27 0
EURL C-5.6 R 100 0 27 0
EURL C-5.7 R 100 0 26 0
EURL C-5.8 R 100 0 26 0
Chloramphenicol, CHL
Tetracycline, TET
Streptomycin, STR
Nalidixic acid, NAL
Gentamicin, GEN
Erythromycin, ERY
Ciprofloxacin, CIP
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Deviations - Salmonella
Lab no. Strain Antimicrobial Obtained interpretation
Obtained 
value
Expected 
interpretation
Expected 
MIC
Method 
used
4 EURL S-5.5 Nalidixic acid, NAL R 16 S =16 MIC
9 EURL S-5.7 Ceftazidime, CAZ R 0.5 S =1 MIC
13 EURL S-5.3 Ampicillin,Â AMP R >32 S =2 MIC
13 EURL S-5.3 Gentamicin, GEN S 4 R =8 MIC
13 EURL S-5.5 Ciprofloxacin, CIP S 0.5 R =1 MIC
13 EURL S-5.6 Ciprofloxacin, CIP S 0.25 R =0.50 MIC
15 EURL S-5.2 Chloramphenicol, CHL R 21 S =8 DD
15 EURL S-5.2 Tetracycline, TET R 18 S =4 DD
15 EURL S-5.4 Nalidixic acid, NAL R 20 S =4 DD
15 EURL S-5.4 Sulfamethoxazole, SMX R 15 S =64 DD
15 EURL S-5.5 Nalidixic acid, NAL R 12 S =16 DD
15 EURL S-5.6 Nalidixic acid, NAL R 15 S =16 DD
15 EURL S-5.6 Sulfamethoxazole, SMX R 15 S =32 DD
15 EURL S-5.7 Ceftazidime, CAZ R 29 S =1 DD
15 EURL S-5.8 Nalidixic acid, NAL R 19 S =4 DD
16 EURL S-5.7 Streptomycin, STR R 32 S =16 MIC
18 EURL S-5.1 Ciprofloxacin, CIP S 24 R =1 DD
18 EURL S-5.2 Ciprofloxacin, CIP S 26 R =1 DD
18 EURL S-5.3 Ciprofloxacin, CIP S 27 R =0.5 DD
18 EURL S-5.3 Gentamicin, GEN S 12 R =8 DD
18 EURL S-5.5 Ciprofloxacin, CIP S 25 R =1 DD
18 EURL S-5.7 Ciprofloxacin, CIP S 28 R =0.25 DD
19 EURL S-5.5 Ciprofloxacin, CIP S 0.06 R =1 MIC
19 EURL S-5.6 Ciprofloxacin, CIP S 0.06 R =0.50 MIC
19 EURL S-5.7 Ciprofloxacin, CIP S 0.06 R =0.25 MIC
20 EURL S-5.2 Nalidixic acid, NAL S <=4 R >64 MIC
20 EURL S-5.7 Nalidixic acid, NAL S <=4 R >64 MIC
24 EURL S-5.8 Confirmed ESBL No Yes MIC
24 EURL S-5.8 Streptomycin, STR R 32 S =16 MIC
26 EURL S-5.7 Streptomycin, STR R 32 S =16 MIC
26 EURL S-5.8 Streptomycin, STR R 32 S =16 MIC
29 EURL S-5.1 Streptomycin, STR S 32 R =64 MIC
32 EURL S-5.7 Ceftazidime, CAZ R <=1 S =1 MIC
33 EURL S-5.5 Nalidixic acid, NAL R 32 S =16 MIC
37 EURL S-5.1 Streptomycin, STR S 32 R =64 AGA
38 EURL S-5.5 Nalidixic acid, NAL R 6 S =16 DD
38 EURL S-5.6 Ciprofloxacin, CIP S 29.5 R =0.50 DD
38 EURL S-5.7 Confirmed ESBL No Yes DD
38 EURL S-5.8 Confirmed ESBL No Yes DD
39 EURL S-5.2 Chloramphenicol, CHL R 256 S =8 MIC
39 EURL S-5.2 Tetracycline, TET R 64 S =4 MIC
39 EURL S-5.5 Cefotaxime, CTX R 4 S <=0.12 MIC
39 EURL S-5.5 Nalidixic acid, NAL R 256 S =16 MIC
39 EURL S-5.5 Tetracycline, TET R 16 S <=2 MIC
39 EURL S-5.7 Confirmed ESBL No Yes MIC
39 EURL S-5.8 Confirmed ESBL No Yes MIC
40 EURL S-5.1 Ciprofloxacin, CIP S 22 R =1 DD
40 EURL S-5.2 Ciprofloxacin, CIP S 21 R =1 DD
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40 EURL S-5.3 Ciprofloxacin, CIP S 27 R =0.5 DD
40 EURL S-5.3 Gentamicin, GEN S 14 R =8 DD
40 EURL S-5.5 Ciprofloxacin, CIP S 26 R =1 DD
40 EURL S-5.6 Ciprofloxacin, CIP S 26 R =0.50 DD
40 EURL S-5.6 Sulfamethoxazole, SMX R 6 S =32 DD
40 EURL S-5.7 Ceftazidime, CAZ R 13 S =1 DD
40 EURL S-5.7 Ciprofloxacin, CIP S 27 R =0.25 DD
40 EURL S-5.7 Sulfamethoxazole, SMX R 6 S =64 DD
40 EURL S-5.7 Tetracycline, TET S 12 R =32 DD
41 EURL S-5.2 Ciprofloxacin, CIP S 0,5 R =1 MIC
41 EURL S-5.3 Ciprofloxacin, CIP S 0,25 R =0.5 MIC
41 EURL S-5.5 Ciprofloxacin, CIP S 0,5 R =1 MIC
41 EURL S-5.6 Ciprofloxacin, CIP S 0,5 R =0.50 MIC
41 EURL S-5.7 Ciprofloxacin, CIP S 0,5 R =0.25 MIC
AGA Agar dilution
DD Disk diffusion
ET E-test
MIC Microbroth dilution
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Deviations - Campylobacter
Lab no. Strain Antimicrobial Obtained 
interpretation
Obtained 
value
Expected 
interpretation
Expected MIC Method 
used
14 EURL C-5.2 Tetracycline, TET S 1 R =16 MIC
15 EURL C-5.2 Tetracycline, TET S 0.38 R =16 AGA
17 EURL C-5.2 Nalidixic acid, NAL S 32 R =64 MIC
19 EURL C-5.3 Streptomycin, STR R 8 S <=1 MIC
19 EURL C-5.4 Streptomycin, STR R 8 S <=1 MIC
19 EURL C-5.4 Tetracycline, TET R 4 S =2 MIC
19 EURL C-5.6 Streptomycin, STR R 8 S <=1 MIC
20 EURL C-5.2 Tetracycline, TET S 2 R =16 MIC
21 EURL C-5.3 Tetracycline, TET R 4 S =1 MIC
21 EURL C-5.4 Streptomycin, STR R 8 S <=1 MIC
21 EURL C-5.6 Streptomycin, STR R 8 S <=1 MIC
21 EURL C-5.7 Ciprofloxacin, CIP R 1 S =0.12 MIC
21 EURL C-5.7 Nalidixic acid, NAL R 64 S =4 MIC
22 EURL C-5.4 Tetracycline, TET R 8 S =2 MIC
22 EURL C-5.5 Erythromycin, ERY R >32 S =0.5 MIC
22 EURL C-5.5 Ciprofloxacin, CIP S 0.25 R =4 MIC
22 EURL C-5.5 Nalidixic acid, NAL S 8 R =64 MIC
22 EURL C-5.5 Streptomycin, STR S 4 R >16 MIC
24 EURL C-5.3 Tetracycline, TET R 4 S =1 MIC
30 EURL C-5.3 Tetracycline, TET R 4 S =1 MIC
30 EURL C-5.4 Tetracycline, TET R 4 S =2 MIC
30 EURL C-5.5 Streptomycin, STR S <= 1 R >16 MIC
32 EURL C-5.2 Nalidixic acid, NAL S <=32 R =64 MIC
41 EURL C-5.4 Nalidixic acid, NAL R 64 S =8 MIC
41 EURL C-5.4 Streptomycin, STR R >16 S <=1 MIC
41 EURL C-5.7 Erythromycin, ERY R >32 S =1 MIC
44 EURL C-5.3 Tetracycline, TET R 8 S =1 AGA
44 EURL C-5.4 Tetracycline, TET R 8 S =2 AGA
44 EURL C-5.6 Streptomycin, STR R 8 S <=1 AGA
AGA Agar dilution
MIC Microbroth dilution
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Optional genotypic characterisation
Lab no. Strain Not 
detected 
Primer used 5’→3’ Primer used 3’→5’ PCR-
method
Reference
I EURL GEN-2.1 catpIP X 5'-GGATATGAAATTTATCCCTC-3' 5'-CAATCATCTACCCTATGAAT-3' In-house
I EURL GEN-2.1 vanA X 5'-AAAGTGCGAAAAACCTTGC-3' 5'-AACAACTTACGCGGCACT-3' In-house
I EURL GEN-2.1 erm(A) X 5'-AAGCGGTAAAACCCCTCTGAG-3' 5'-TCAAAGCCTGTCGGAATTGG-3' In-house
I EURL GEN-2.1 emtA X 5'-GGTCAGCAGATCACTTGTTT-3' 5'-TGAACAATTCTAAGTCCTCG-3' In-house
I EURL GEN-2.1 vat(D) X 5'-GCTCAATAGGACCAGGTGTA-3' 5'-TCCAGCTAACATGTATGGCG-3' In-house
I EURL GEN-2.1 vat(E) X 5'-ACTATACCTGACGCAAATGC-3' 5'-GGTTCAAATCTTGGTCCG-3' In-house
I EURL GEN-2.1 vgbA X 5'-TACAGAGTACCCACTACCGA-3' 5'-TCAATTCCTGCTCCAGCAGT-3' In-house
I EURL GEN-2.1 tet(O) X 5'-GATGGCATACAGGCACAGAC-3' 5'-CAATATCACCAGAGCAGGCT-3' In-house
I EURL GEN-2.1 tet(S) X 5'-TGGAACGCCAGAGAGGTATT-3' 5'-ACATAGACAAGCCGTTGACC-3' In-house
I EURL GEN-2.1 aadE 5'-TCAAAACCCCTATTAAAGCC-3' 5'-ATGGAATTATTCCCACCTGA-3' In-house
I EURL GEN-2.1 aph(3´)-III 5'-GCCGATGTGGATTGCGAAAA-3' 5'-GCTTGATCCCCAGTAAGTCA-3' In-house
I EURL GEN-2.1 vanB 5'-GATATTCAAAGCTCCGCAGC-3' 5'-TGATGGATGCGGAAGATACC-3' In-house
I EURL GEN-2.1 erm(B) 5'-GGAACATCTGTGGTATGGCG-3' 5'-CATTTAACGACGAAACTGGC-3' In-house
I EURL GEN-2.1 pbp5 5-'TGAGCAATT TGTCCAAGC-3' 5'-TGATCCAGCTTTTCCTCC-3' In-house
I EURL GEN-2.1 tet(K) 5'-TTAGGTGAAGGGTTAGGTCC-3' 5'-GCAAACTCATTCCAGAAGCA-3' In-house
I EURL GEN-2.1 tet(L) 5'-CATTTGGTCTTATTGGTACG-3' 5'-ATTACACTTCCGATTTCGG-3' In-house
I EURL GEN-2.1 tet(M) 5'-GTTAAATAGTGTTCTTGGAG-3' 5'-CTAAGATATGGCTCTAACAA-3' In-house
I EURL GEN-2.2 CMY X In-house
I EURL GEN-2.2 SHV X In-house
I EURL GEN-2.2 TEM X In-house
I EURL GEN-2.2 cmlA X In-house
I EURL GEN-2.2 floR X In-house
I EURL GEN-2.2 aac(3)-II X 5'-TGAAACGCTGACGGAGCCTC-3' 5'-GTCGAACAGGTAGCACTGAG-3' In-house
I EURL GEN-2.2 aac(3)-IV X In-house
I EURL GEN-2.2 ant(2'')-I X In-house
I EURL GEN-2.2 aph(3')-I X 5'-AACGTCTTGCTCGAGGCCGCG-3' 5'-GGCAAGATCCTGGTATCGGTCTGCG-3' In-house
I EURL GEN-2.2 aph(3')-III X 5'-GCCGATGTGGATTGCGAAAA-3' 5'-GCTTGATCCCCAGTAAGTCA-3' In-house
I EURL GEN-2.2 qnrA X 5'-GGATGCCAGTTTCGAGGA-3' 5'-TGCCAGGCACAGATCTTG-3' In-house
I EURL GEN-2.2 qnrB X In-house
I EURL GEN-2.2 qnrC X 5’-GGGTTGTACATTTATTGAATC-3’ 5’-TCCACTTTACGAGGTTCT-3’ In-house
I EURL GEN-2.2 qnrD X 5’-CGAGATCAATTTACGGGGAATA-3’ 5’-AACAAGCTGAAGCGCCTG-3’ In-house
I EURL GEN-2.2 qnrS X In-house
I EURL GEN-2.2 sul1 X In-house
I EURL GEN-2.2 sul3 X In-house
I EURL GEN-2.2 tetA X In-house
I EURL GEN-2.2 tetC X In-house
I EURL GEN-2.2 tetD X In-house
I EURL GEN-2.2 tetE X In-house
I EURL GEN-2.2 tetG X In-house
I EURL GEN-2.2 CTX -M-9* 5'-GTGTGTTTAGAATGGTGATCGCATT-3' 5'-ATGATTCTCGCCGCTGAAGCC-3' In-house
I EURL GEN-2.2 OXA In-house
I EURL GEN-2.2 catA1 In-house
I EURL GEN-2.2 aadA In-house
I EURL GEN-2.2 strA In-house
I EURL GEN-2.2 strB In-house
I EURL GEN-2.2 sul2 In-house
I EURL GEN-2.2 tetB In-house
Gene tested
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III EURL GEN-2.2 CMY X Published Zhao et al. 2003 JCM
III EURL GEN-2.2 SHV none X Published Guerra et al 2004 MDR 10:83-91
III EURL GEN-2.2 TEM none X Published Guerra et al 2004 MDR 10:83-91
III EURL GEN-2.2 cmlA X Published Guerra et al 2004 MDR 10:83-91
III EURL GEN-2.2 floR X Published Guerra et al 2004 MDR 10:83-91
III EURL GEN-2.2 aac(3)-II X ATTCGAAAACTCGGAGTC CGGAGTGGCTCCGAAGTG In-house
III EURL GEN-2.2 aac(3)-IV X Published Guerra et al 2004 MDR 10:83-91
III EURL GEN-2.2 ant(2'')-I X Published Frana et al. 2001 AEM 67:445-8
III EURL GEN-2.2 aph(3')-I X Published Frana et al. 2001 AEM 67:445-8
III EURL GEN-2.2 aph(3')-II X Published Frana et al. 2001 AEM 67:445-8
III EURL GEN-2.2 aph(3')-III X Published Gibreel et al. 2004; AAC
III EURL GEN-2.2 gyrA-87 X Published Malorny et al., Vet Rec. 2003
III EURL GEN-2.2 parC-57 X Published Malorny et al., Vet Rec. 2003
III EURL GEN-2.2 parC-78 X Published Malorny et al., Vet Rec. 2003
III EURL GEN-2.2 parC-84 X Published Malorny et al., Vet Rec. 2003
III EURL GEN-2.2 qnrA X Published Wang et al., 2003
III EURL GEN-2.2 qnrB X Published Jacoby et al., 2006
III EURL GEN-2.2 qnrC X Published Wang et al., 2009
III EURL GEN-2.2 qnrD X Published Cavaco et al., 2009
III EURL GEN-2.2 qnrS X Published Gay et al., 2006
III EURL GEN-2.2 sul1 X Published Sadvang et al., 1997 FEMS Mic Let
III EURL GEN-2.2 sul3 X Published Perreten-Boerlin 2003
III EURL GEN-2.2 tetA X Published Ng, Lai King 1999 AAC
III EURL GEN-2.2 tetC X Published Ng, Lai King 1999 AAC
III EURL GEN-2.2 tetD X Published Ng, Lai King 1999 AAC
III EURL GEN-2.2 tetE X Published Ng, Lai King 1999 AAC
III EURL GEN-2.2 tetG X Published Ng, Lai King 1999 AAC
III EURL GEN-2.2 CTX -M-14 Published Batchelor JCM2005; Carattoli et al.,
III EURL GEN-2.2 OXA -1 Published Guerra et al 2004 MDR 10:83-91
III EURL GEN-2.2 catA1 Published Guerra et al 2004 MDR 10:83-91
III EURL GEN-2.2 gyrA -83 Published Malorny et al., Vet Rec. 2003
III EURL GEN-2.2 parC -80 Published Malorny et al., Vet Rec. 2003
III EURL GEN-2.2 aadA Published Sadvang et al., 1997 FEMS Mic Let
III EURL GEN-2.2 strA Published Madsen et al. 2000 VetMic 75:73-82
III EURL GEN-2.2 strB Published Madsen et al. 2000 VetMic 75:73-82
III EURL GEN-2.2 sul2 Published Chu et al., 2001 AAC
III EURL GEN-2.2 tetB Published Ng, Lai King 1999 AAC
IV EURL GEN-2.2 CTX
IV EURL GEN-2.2 OXA
IV EURL GEN-2.2 catA1
IV EURL GEN-2.2 aadA
IV EURL GEN-2.2 strA
IV EURL GEN-2.2 strB
IV EURL GEN-2.2 sul2
IV EURL GEN-2.2 tetB
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V EURL GEN-2.2 SHV none X AGGATTGACTGCCTTTTTG ATTTGCTGATTTCGCTCG Published Colom et al FEMS Micro Lett (2003) 223(2):147-5
V EURL GEN-2.2 TEM none X ATCAGCAATAAACCAGC CCCCGAAGAACGTTTTC Published Colom et al FEMS Micro Lett (2003) 223(2):147-5
V EURL GEN-2.2 cmlA X TGTCATTTACGGCATACTCG ATCAGGCATCCCATTCCCAT Published Guerra et al JAC (2003) 52:489-492
V EURL GEN-2.2 qnrA X ATTTCTCACGCCAGGATTTG GATCGGCAAAGGTTAGGTCA Published Robiscek et al AAC (2006) 50(8):2872-4.
V EURL GEN-2.2 qnrB X GATCGTGAAAGCCAGAAAGG ACGATGCCTGGTAGTTGTCC Published Robiscek et al AAC (2006) 50(8):2872-4.
V EURL GEN-2.2 qnrS X ACGACATTCGTCAACTGCAA TAAATTGGCACCCTGTAGGC Published Robiscek et al AAC (2006) 50(8):2872-4.
V EURL GEN-2.2 sul1 X TCACCGAGGACTCCTTCTTC AATATCGGGATAGAGCGCAG Published Walker et al MDR (2001) 7:13-21.
V EURL GEN-2.2 sul3 X ACCGATAGTTTTTCCGATGG TGCGGAGATAATCTGCACCT In-house
V EURL GEN-2.2 tetA X CATAGATCGCCGTGAAGAGG CATAGATCGCCGTGAAGAGG Published Ng et al AAC (1999) 43:3018-3021.
V EURL GEN-2.2 tetC X CTTGAGAGCCTTCAACCCAG ATGGTCGTCATCTACCTGCC Published Ng et al AAC (1999) 43:3018-3021.
V EURL GEN-2.2 tetD X AAACCATTACGGCATTCTGC GACCGGATACACCATCCATC Published Ng et al AAC (1999) 43:3018-3021.
V EURL GEN-2.2 CTX -M-14 ATGGTGACAAAGAGAGTGCAAC TTACAGCCCTTCGGCGATG Published Batchelor et al AAC (2005) 49:1319-1322.
V EURL GEN-2.2 OXA -30 ATATCTCTACTGTTGCATCTCC AAACCCTTCAAACCATCC Published Colom et al FEMS Micro Lett (2003) 223(2):147-5
V EURL GEN-2.2 catA1 CGCCTGATGAATGCTCATCCG CCTGCCACTCATCGCAGTAC Published Aarestrup et al JAC (2003) 52:715-718.
V EURL GEN-2.2 gyrA -83 TGTCCGAGATGGCCTGAAGC TACCGTCATAGTTATCCACG Published Griggs et al AAC (1996) 40(4):1009-13
V EURL GEN-2.2 aadA TATCAGAGGTAGTTGGCGTCAT GTTCCATAGCGTTAAGGTTTCATT Published Randall et al JAC (2004) 53:208-216.
V EURL GEN-2.2 strA CAACTGGCAGGAGGAACA CGCAGATAGAAGGCAAGG Published Hopkins et al MDR (2007) 13:281-288.
V EURL GEN-2.2 strB TTCTCATTGCGGACACCT GGCATTGCTCATCATTTG In-house
V EURL GEN-2.2 sul2 CCGTCTCGCTCGACAGTTAT GTGTGTGCGGATGAAGTCAG In-house
V EURL GEN-2.2 tetB TTGGTTAGGGGCAAGTTTTG GTAATGGGCCAATAACACCG Published Ng et al AAC (1999) 43:3018-3021.
Legend: 
Fields shaded grey indicate that the detected gene was expected
Genes in bold were detected but not expected 
*CTX-M-9-group recorded (which also includes the CTX-M-14 variant)
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